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The pharmacokinetics of orally administered ranitidine were studied in 
10 patients with endoscopically proved duodenal ulceration after a single 
150 mg dose and after 4 weeks 1 ranitidine treatment (150 mg twice daily), 
at which time there was endoscopic evidence of complete ulcer healing. 
After a single dos~ the median elimination half-life was 135 minutes and 
the median area under the curve (AUC) was l 844 ng/ml .hr. Although the 
maximum concentration after a single dose (Cmax = 365 ng/ml) was 
significantly different from that after continuous treatment (Cmax = 
562 ng/ml) (p <0,05) there was no significant difference between the 
minimum concentrations at 12 hours post-dosing (Cmin = 35 ng/ml and 
30 ng/ml respectively) and the median half-lives were identical. No 
accumulation of ranitidine occurred in these patients after 4 weeks 1 
chronic ranitidine treatment. 
Five patients received 20 mg ranitidine intravenously. The apparent 
volume of distribution of the central compartment ranged from 10,5 to 
28,4 1 while the elimination rate constant B range drom 0,34 to 0,78 h-l 
with the t 1 ranging from 53 to 122 minutes. The mean oral bioavailability 
2 
was 51%. 
The phannacokinetics of ranitidine were studied in a further 7 patients 
with chronic duodenal ulceration who showed endoscopic evidence of unhealed 
ulcers after at least 8 weeks 1 treatment with ranitidine. There were no 
significant differences in any of the pharmacokinetic parameters when 
these patients were compared with the 10 responders above after multiple-
dosage except that the disposition rate constant was smaller in non-
responders (0,24 h-l compared with 0,31 h- 1 , p <0,002). T1\fo patients did, 
however, have very low plasma concentrations with above average basal 
and maximal acid output which may have contributed to the lack of 
response to ranitidine treatment. 
i i i 
Single- and multiple-dose pharmacokinetic studies of oral ranitidine 
were carried out in 6 patients with chronic renal failure (RF) 
(creatinine clearance <25 ml/min) and compared with those obtained for 
the 10 patients with chronic duodenal ulceration with normal renal 
function (creatinine clearance >65 ml/min). There appeared to be no 
significant differences in absorption rate or amount absorbed but the 
median elimination rate constant was significantly reduced from 0,31 h-l 
in controls to 0,14 h-l in RF (p <0,002) resulting in a two-fold increase 
in t 1 (312 minutes) after a single dose. Cmax did not differ significantly 
2 
although Cmin and ALIC were significantly larger in RF patients (both 
p <0,002). It is suggested that the dosage of ranitidine be reduced 
from 150 mg to 75 mg twice daily in severe renal failure although it was 
not possible to relate half-life, elimination rate constant or ALIC 
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l. INTRODUCTION AND LITERATURE REVIEW 
1.1. INTRODUCTION 
The discovery by Black and co-workers in 1972 of a specific antagonist 
to the effects of histamine at the histamine H2-receptor heralded a new 
era in the research into mechanisms of gastric secretion and added a new 
dimension to the treatment of peptic ulceration. Cimetidine, the only 
H2-antagonist to become generally available, has been used to treat 
millions of patients suffering from peptic ulceration. The evidence 
attesting to the efficacy of cimetidine treatment for duodenal ulceration 
is overwhelming (Bardhan 1980, Domschke et al 1980, Grossman 1980). 
Cimetidine has in fact become the yardstick against which other anti-
ulcer drugs are measured (Marks et al 1980, Vantrappen et al 1980). 
However, as with all phannacologically effective compounds, unwanted effects 
do occur although the incidence is relatively low in short-term treatment 
(Domschke et al 1980, Kruss et al 1979). Patients with renal failure or 
hepatic failure and the aged are at particular risk of developing more 
serious side-effects such as mental status changes (Bleumink 1980, Fastner 
1980) probably due to reduced clearance of the drug. 
At present there are new H2-receptor antagonists which are more potent 
than cimetidine undergoing investigation (Domschke et al 1980). Ranitidine 
is an H2-antagonist which differs from cimetidine in that the imidazole 
ring has been replaced by a furan ring (Peden et al 1979). Ranitidine is 
claimed to be more potent than cimetidine, and a simplified dosage schedule 
has been proposed. It may cause fewer side-effects. 
Limited phannacokinetic studies of ranitidine have been carried out in 
healthy volunteers (McNeil et al 1980, Woodings et al 1980). No phannaco-
kinetic studies have as yet been published on a patient population. The 
phannacokinetic behaviour of a drug in healthy man is not necessarily a 
true reflection of the situation in patients as the disease state may alter 
absorption, distribution, metabolism or elimination, thereby reducing 
efficacy or increasing toxicity. 
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I have therefore conducted the following studies into the pharmacokinetics 
of ranitidine following oral administration in patients suffering from 
chronic duodenal ulceration and in patients with severe renal failure and 
also a limited study of intravenous ranitidine in patients with chronic 
duodenal ulceration. 
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1.2. THE HISTORY OF THE H2-RECEPTOR ANTAGONISTS 
The histamine H1-receptor antagonised by the conventional antihistaminic 
drugs such as mepyramine was defined by Ash and Schild in 1966. It was 
recognized that there was another class of histamine receptors which was 
not antagonised by the conventional or H1-receptor antihistaminics. 
Black and co-workers commenced a search for antagonists to the effects 
of histamine on gastric secretion, heart rate and contractions of the 
rat uterus, using the analogy with catecholamine receptors and working 
from the structure of histamine. In 1972 Black et al published a report 
defining the histamine H2-receptor and announcing the discovery of burima-
mide, a specific antagonist at the H2-receptor (Figure 1.1.) (Black et al 
1972). 
The structure of burimamide was then modified slightly to give the more 
potent orally active compound metiamide (Black et al 1973). Metiamide, 
although of therapeutic value in duodenal ulcer disease (Multicentre 
Trial 1975) was not marketed as it caused agranulocytosis (Burland et al 
1975). The toxicity was thought to be related to the thiourea moeity in 
the side chain (Figure 1. 1.) and this was changed to a cyanoguanidine 
to give cimetidine (Brimblecombe et al 1975) which was found to be an 
effective inhibitor of gastric acid secretion in animals in response to 
various stimuli.including histamine and pentagastrin (Parsons 1977). 
Studies carried out in man confirmed these results both in healthy 
volunteers (Aadland et al 1977, Misiewicz 1976, Pounder et al 1976a, 
Pounder et al 1976b) and in duodenal ulcer patients (Longstreth 1976, 
Richardson et al 1975a, Richardson 1975b). 
Many placebo-controlled trials of cimetidine have confirmed its efficacy 
in prrnnoting the healing of duodenal ulcers when administered over a 
period of 4 to 6 weeks (Bank et al 1976, Bodemar and Walan 1976, Burland 






Figure 1.1. The structures of histamine and some H2-receptor antagonists. 
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The percentage healing rate with cimetidine varied in these reports from 
67 to 97%. 
The position of cimetidine in the treatment of gastric ulcer is controversial 
as some trials show cimetidine to be more effective than placebo (Dyck et 
al 1978, Frost et al 1977) and as effective as carbenoxo1one with fewer 
side-effects (La Brooy et al 1979) while others have shown little difference 
between the effects of cimetidine and placebo (Finkelstein and Isse1bacher 
1978, Grossman 1980). There have been recent suggestions that cimetidine 
may mask or even promote malignant changes in the gastric mucosa (Elder 
et al 1979a, Reed et al 1979, Taylor et al 1979) possibly through the 
formation of nitrosocimetidine (Elder et al 1979b). Cimetidine has 
proved useful in the control of peptic ulceration associated with the 
Zollinger-Ellison syndrome although in most cases a larger than normal 
dosage was necessary (3rogden et al 1978, McCarthy et al 1978). 
Clinical experience has shown cimetidine to be relatively free of side-
effects in the short-term with minor side-effects such as headache, 
dizziness, fatigue, skin rash, diarrhoea, constipation and muscular pain 
occurring with the same incidence as in placebo-treated groups (Brogden et 
al 1978, Finkelstein and Isselbacher 1978). Since H2-receptors are 
distributed throughout the body including the brain and the heart, 
theoretically the potential for side-effects involving these systems 
exists. Cimetidine has been linked with changes in mental status such as 
depression, lethargy, coma, restlessness, agitation, disorientation, con-
fusion, delirium, unsteadiness, visual impairment, hallucinations and 
somnolence (Russell and Langley 1980). Breast pain, ga1actorrhoea and 
more frequently gynaecomastia with or without raised prolactin levels, have 
been mainly reported in patients on long-tenn therapy (Bleumink 1980). 
Impotence in a number of duodenal ulcer patients on cimetidine has been 
reported (Bleumink 1980) and is thought to be due to anti-androgenic 
properties of the drug (Sawyer et al 1981). 
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Haematological abnonnalities such as agranulocytosis and pancytopenia 
have occurred in a small number of patients taking cimetidine although 
the role played by cimetidine is uncertain (Bleumink 1980, Fastner 1980). 
Drug-drug interactions between cimetidine and the oral anticoagulants are 
of clinical importance (Flind 1978, Serlin et al 1979, Silver and Bell 1979). 
A potentiation of the effects of coumarin anticoagulants is due to 
inhibition of their metabolism by cimetidine inhibition of microsomal drug 
metabolism (Park and Breckenridge 1981, Puurunen et al 1980). Cimetidine 
similarly prolongs the half-life of other drugs metabolised by cytochrome 
P-450 such as chlordiazepoxide (Desmond et al 1980) and diazepam (Klotz 
et al 1979). 
New H2-antagonists with increased potency in relation to cimetidine are 
at present undergoing investigation (Domschke and Domschke 1980). 
Ranitidine is an H2-antagonist which differs from histamine and cimetidine 
in that the imidazole ring which was thought at one stage to be essential 
for H2-receptor blockade (Ganellin et al 1976) has been replaced with a 
furan ring (Figure 1. l.) (Bradshaw et al 1979). 
Experiments on the guinea pig atrium and rat uterus in-vitro have 
demonstrated competitive antagonism by ranitidine to the effects of 
histamine without altering responses to isoprenaline (Daly et al 1980a, 
Daly et al 1981). Ranitidine inhibited pentagastrin- and histamine-induced 
gastric acid secretion in the perfused stomach preparation of the 
anaesthetized rat where it was 7 times more potent than cimetidine on a 
molar basis (Daly et al 1981). The effects of oral ranitidine in inhibiting 
gastric acid secretion stimulated by histamine, pentagastrin and bethanechol 
in Heidenhain-pouch dogs were 4,3, 5,0, 9,2 times more potent than those 
of cimetidine respectively (Daly et al 1980b). In chronic gastric fistula 
rats and Heidenhain-pouch dogs the comparative potency in inhibition of 
gastric acid output of 4 H2-antagonists was cimetidine < BL-5641 < Ranitidine 
< IC! 125211 (Cavanagh et al 1980). In the dog with a gastric fistula, 
food- and 2-deoxy-D-glucose-induced acid secretion was inhibited by 
ranitidine (Daly et al 1979). 
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Ranitidine is a selective H2-antagonist in-vitro and in-vivo it is active 
after oral administration in animals in inhibiting histamine-induced 
gastric acid secretion as well as the effects of other secretagogues 
(pentagastrin, bethanechol, food and 2-deoxy-D-glucose). 
Other H2-antagonists at present under investigation include SK&F 92994, 
!CI 125211 (Domschke and Domschke 1980) and BL-5641 (Cavanagh et al 1980). 
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1.3. CLINICAL PHARMACOLOGY OF RANITIDINE. 
Studies carried out in healthy volunteers have shown ranitidine to inhibit 
pentagastrin-stimulated gastric acid secretion when administered intra-
venously (Domschke et al 1979, Kett et al 1980, Sewing et al 1980, Woodings 
et al 1980) and orally (Simon and Kather 1979). Intravenous ranitidine 
significantly reduced histamine-stimulated gastric acid and volume output 
in nonnal subjects (Bohman et al 1980). When administered intravenously 
to volunteers, ranitidine was found to be 6-times more effective than 
cimetidine in raising gastric transmural electrical potential (Von Kleist 
et al 1979). Cimetidine and ranitidine inhibit gastric acid secretion 
induced in volunteers by amino acid infusion (Weingart et al 1980). 
A comparative study of ranitidine and cimetidine in patients with duodenal 
ulcer in clinical remission showed ranitidine to be 8-times more potent 
than cimetidine in inhibiting histamine-induced secretion and 4- to 5-
times more potent as an inhibitor of sham- and real-feeding-induced 
secretion without affecting serum gastrin levels (Konturek et al 1980). 
Ranitidine given orally (100 mg) to 6 patients caused a clear increase 
of intra-gastric pH for over 9 hours (Damman et al 1980). In patients 
with clinically active duodenal ulceration, ranitidine was a powerful 
inhibitor of nocturnal and pentagastrin-stimulated gastric acid secretion 
(Peden et al 1979a). In 5 of these patients 50% inhibition of penta-
gastrin-stimulated acid secretion was achieved at a mean plasma ranitidine 
concentration (IC50 ) of 93,6 ng/ml after intraduodenal administration 
(Peden et al 1979b). 
After 6 weeks of ranitidine treatment, 94% of patients with gastric 
ulceration and 83% of patients with duodenal ulceration showed endoscopic 
evidence of healing in an open study (Barbier et al 1979). 
In a double-blind placebo-controlled trial of patients with duodenal 
ulceration, ranitidine given in a dose of 100 mg twice daily for 4 weeks 
healed 92% compared to 46% healing in the placebo group (Berstad et al 1980). 
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In another double-blind placebo-controlled trial with 150 mg ranitidine 
administered twice daily, 80% of ulcers were healed compared with 33% in 
the placebo group (Chatterji 1980). Cimetidine 1000 mg daily and ranitidine 
200 mg daily were proved equivalent in promoting ulcer healing (94% and 89% 
healing respectively after 8 weeks' treatment) (Langman et al 1980). 
It is hoped that the side-effects of cimetidine which are unrelated to 
H2-receptor blockade may be avoided with more potent drugs such as ranitidine 
where the imidazole ring has been replaced. Thus far ranitidine does see~ 
to have an advantage over cimetidine with respect to some of the side-
effects. Ranitidine does not appear to influence cardiac function (Barbat 
and Warrington 1980). When administered intravenously, ranitidine had no 
effect on prolactin levels (Barbat and Warrington 1980). Cimetidine, but 
not ranitidine, tends to raise blood teststerone levels in peptic ulcer 
patients (Walt et al 1981). One patient with Zollinger-Ellison syndrome 
was successfully treated for duodenal ulceration with ranitidine after 
having to discontinue cimetidine treatment because of painful gynaecomastia 
(Mignon et al 1980). In a clinical trial in which ranitidine (200 mg daily) 
and cimetidine (l g daily) were compared, cimetidine caused significant 
increases in serum urea and creatinine concentrations although still within 
the nonnal range, whereas ranitidine had no effect (Langman et al 1980). 
The inhibition of the metabolism of a number of drugs including warfarin 
(Serlin et al 1979), chlordiazepoxid (Desmond et al 1980), antipyrine 
(Puurunen et al 1980), diazepam (Klotz et al 1979) by cimetidine has been 
attributed to the imidazole ring structure (Wilkinson et al 1973). 
These interactions might be expected to be absent when using ranitidine. 
In a paired study of hepatic microsomal function in 8 subjects, ranitidine 
(200 mg daily) did not affect the metabolism of aminopyrine or antipyrine 
whereas cimetidine (l g daily) did so (Henry et al 1980). Another study 
of ranitidine (150 mg daily for one week) showed no effect of the drug on 
antipyrine half-life, clearance or volume of distribution (Staiger et al 
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1980). In patients being treated with drugs metabolised by cytochrome 
P-450, ranitidine would seem to be a suitable alternative to cimetidine. 
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1.4. PHARMACOKINETICS AND BIOAVAILABILITY OF H2-RECEPTOR ANTAGONISTS. 
The H2-antagonist metiamide was developed when the original H2-antagonist 
burimamide was found to be inactive orally (Black et al 1973). The bone-
marrow toxicity of metiamide limited its clinical usefulness and led to 
the development of cimetidine. 
Several studies of cimetidine blood levels after intravenous and oral 
administration have been carried out in healthy humans (Burland et al 1975b, 
Grahnen et al 1979, Griffiths et al 1977, Tayler et al 1978, Walkenstein 
et al 1978). Following oral administration, cimetidine is rapidly absorbed 
with ~he peak occurring from 0,5 to 2 hours after dosing (Griffiths et al 
1977, Walkenstein et al 1978) and a marked secondary peak 2 to 5 hours 
after dosing when administered on a fasting stomach (Griffiths et al 1977, 
Grahnen et al 1979, Walkenstein et al 1978). Bioavailability after oral 
dosage has been reported variously as 62% (Walkenstein et al 1978), 72% 
(Griffiths et al 1977) and over 100% in most subjects in a third study 
(Grahnen et al 1979). Grahnen has proposed that bioavailability of greater 
than 100% may be explained by entero-hepatic recycling (Grahnen et al 1979). 
A phannacokinetic model taking into account the discontinuous absorption 
following recycling has been constructed and has shown good agreement with 
oral, intravenous and intramuscular data (Veng Pedersen and Miller 1980). 
In healthy humans, antacids administered with cimetidine after a meal did 
not interfere with cimetidine absorption (Burland et al 1976) but in peptic 
ulcer patients antacids taken with cimetidine on a fasting stomach caused 
a reduction in blood concentrations of cimetidine (Bodemar et al 1979b). 
After intravenous administration cimetidine blood concentration data fit 
a two-compartment open model (Grahnen et al 1979, Griffiths et al 1977) 
with the initial distribution phase having a short half-life of 
approximately 7 minutes (Griffiths et al 1977). The tenninal elimination 
phase half-life is usually between l ,8 and 2 hours (Burland et al 1975b, 
Grahnen et al 1979, Griffiths et al 1977, Walkenstein et al 1978) and does 
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not differ with different routes of administration. In most studies 
70 to 80% of the parent drug is excreted in the unchanged form in the 
urine when cimetidine is administered intravenously (Griffiths et al 1977, 
Taylor et al 1978, Walkenstein et al 1978) but only 40 to 50% is recovered 
in the urine after oral dosage (Grahnen et al 1979, Walkenstein et al 
1978). Approximately 10% is found as the sulphoxide metabolite in urine 
(Burland et al 1975b, Griffiths et al 1977) independent of dose or route 
of administration. A four-fold bile to blood concentration gradient has 
been recorded although the total amount of drug secreted was insignificant 
when compared to the dose (Spence et al 1977). There is some evidence that 
cimetidine is excreted in human breast milk (Wilson et al 1980). 
In-depth pharmacokinetic studies of cimetidine in peptic ulcer patients 
are few and have only recently been published. Henn showed a direct 
relationship between inhibition of meal-stimulated gastric acid secretion 
and peak blood cimetidine concentration in ulcer patients on oral treatment 
(Henn et al 1975). A study in 28 patients with peptic ulcer treated with 
oral cimetidine showed no change in bioavailability over 12 weeks of 
treatment as assessed by area under the curve (AUC). The AUC was dose-
related and there was no difference in bioavailability when the drug was 
taken on a fasting stomach or together with a meal (Bodemar et al 1979a). 
This study also demonstrated a secondary peak when cimetidine was given 
on an empty stomach which was not seen when the drug was given with food 
(Bodemar et al 1979a). Somogyi et al compared the phannacokinetics and 
bioavailability of 200 mg cimetidine given intravenously and orally in 6 
gastric and 6 duodenal ulcer patients (Somogyi et al 1980a). There were 
no phannacokinetic differences between the two ulcer groups although a 
considerable age-related variation in pharmacokinetic parameters was 
noted (Somogyi et al 1980a). 
Rune et al (1979) measured acid secretion and its inhibition by cimetidine 
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in 40 duodenal ulcer patients. They also measured cimetidine blood 
concentrations in order to examine why some patients were resistant to 
standard cimetidine therapy. They demonstrated a wide inter-individual 
variation in sensitivity to cimetidine and a low correlation of acid 
inhibition with AUC. There was no correlation of effectiveness with 
gastric secretory capacity or individual sensitivity to cimetidine (Rune 
et al 1979). In a report on one patient, cimetidine was found to have 
no effect on acid secretion despite apparently adequate plasma levels 
and the author suggests that gastric secretory studies in non-responders 
are necessary to identify patients of this type (Kisloff 1980). 
There is as yet very little human pharmacokinetic information available 
on the newer H2-antagonists. SK&F 92994, a compound with an isocytosine 
ring in its side-chain, is more potent than cimetidine and a dosage 
schedule of 400 mg twice daily has been suggested (Gotthard et al 1980). 
In patients with duodenal ulceration the half-life of SK&F 92994 was 
about 3,3 hours and the bioavailability 36% (Somogyi and Gugler 1980b). 
Ranitidine is reported to have an elimination half-life of approximately 
two hours (McNeil et al 1980, Woodings et al 1980). Bioavailability is 
about 50% and peak levels occur 0,5 to 1 ,5 hours after dosage; secondary 
peaks were observed when administered on a fasting stomach (Woodings et 
al 1980). The total apparent volume of distribution is 115 litres and 
the total plasma clearance is estimated at 709 ml/min (McNeil et al 
1980). Ranitidine is excreted chiefly in unchanged fonn in the urine 
with small amounts of N-oxide, S-oxide and desmethyl metabolites (Bell 
et al 1980). All these studies involved healthy volunteers and to date 
no ranitidine pharmacokinetic data in duodenal ulcer patients have been 
published. 
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l .5. H2-ANTAGONISTS AND RENAL IMPAIRMENT. 
There is an incidence of peptic ulceration and gastrointestinal bleeding 
in patients with chronic renal failure and this incidence further 
increases (~p to 50%) when patients are managed with chronic haemo-
dialysis (Doherty et al 1977, Shepherd et al 1973, lformsley 1980). 
Gastric output is high in uraemic patients, particularly in those on 
regular haemodialysis (Doherty et al 1977, Shepherd et al 1973) and hyper-
gastrinaemia is often observed as we1l (Doherty et al 1977, Doherty et al 
1978a). After renal transplantation the occurrence of peptic ulceration 
varies from 4,4 to 18% and a high proportion of these patients experience 
complications (Editorial 1979, Perrott et al 1981). H2-antagonists might 
therefore be expected to be of benefit in the prevention or treatment of 
upper gastrointestinal problems in chronic renal impairment. 
Two reports confirm the therapeutic efficacy of cimetidine in patients 
with renal impairment (Doherty et al 1977, Jones et al 1979) although 
there are conflicting reports on its prevention of upper gastrointestinal 
complications after kidney transplantation (Doherty et al 1978b, Hussey 
and Belzer 1979). Cimetidine is mainly eliminated unchanged by the 
kidneys (Burland et al 1975) and tends to accumulate in patients with 
renal disease or age-related reduction in renal function. There is some 
evidence to suggest that side-effects such as mental confusion may be 
related to relatively high cimetidine concentrations, particularly in 
patients with renal or hepatic dysfunction or in the elderly (Russell and 
Lopez 1980, Schentag et al 1979). A study in healthy subjects showed a 
significant correlation between AUC and age although the correlation of 
AUC with creatinine clearance was poor (Redolfi et al 1979). Another 
study showed total plasma clearance and volume of distribution of 
cimetidine to be inversely related to age (Somogyi et al 1980a). Elderly, 
healthy individuals have slower metabolic and renal removal of drugs in 
general (Crooks et al 1976) and dosages may have to be adjusted for this 
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group of patients as well as those patients in renal failure. 
A number of studies of cimetidine blood levels in patients with impaired 
renal function (Bjaeldager et al 1980, Canavan and Briggs 1977, Larsson 
et al 1979, Luk et al 1979) and hepatic dysfunction (Schentag et al 1979) 
have appeared in the literature. After intravenous administration, the 
elimination half-life of cimetidine was significantly longer (2,56 h) than 
in normals (1 ,52 h) although in anephric patients the half-life was shorter 
than expected (3,66 h) indicating greater use of alternative pathways 
(Ma et al 1978). Similar results were obtained in two other studies where 
oral cimetidine was administered (Bjaeldager et al 1980, Larsson et al 
1979) showing slower elimination and higher blood levels in uraemic 
patients. Various methods of calculation of dosage adjustments have 
been advocated including one based on AUC (Bjaeldager et al 1980) a 
nomogram relating dosage to creatinine clearance (Luk et al 1979), and 
another based on the length of time blood cimetidine concentrations 
remained above O ,5 µg/ml (Larsson et al 1979). 
The above studies all gave similar results and Bennett et al (1980) 
recommend the following dosage guidelines to patients with: 
i) glomerular filtration rate (GFR) exceeding 50 ml/min, dose and 
dosage interval remain unaltered at 200 mg 6-hourly; 
ii) GFR of 10 to 50 ml/min, 150 mg 6-hourly or 200 mg 8-hourly; 
iii) GFR below 10 ml/min, 100 mg cimetidine 6-hourly or 200 mg 12-hourly. 
The efficacy of 200 mg cimetidine when given 12-hourly for 6 weeks in the 
treatment of various upper gastrointestinal peptic disturbances (including 
duodenal ulcer, oesophagitis, and erosions) in 8 patients undergoing 
haemodialysis without undesirable side-effects, has been confirmed by 
Jones et al (1979). 
Cimetidine is dialysable (Bjaeldager et al 1980, Canavan and Briggs 1977, 
Ma et al 1978) although the amount varies in the different reports. ~a 
et al recommend an extra dose at the end of dialysis but Bjaeldager et 
17 
al consider this unnecessary (Ma et al 1978, Bjaeldager et al 1980). 
There is no information available on the blood levels of any of the new 
H2-antagonists in patients with renal failure. Ranitidine, which like 
cimetidine, undergoes elimination in the unchanged form in the urine to 
a large extent (Bell et al 1980), can be expected to have a similar 
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2.1. PATIENT STUDY DESIGN. 
Separate protocols were drawn up for each aspect of the trial and 
submitted to the South African Medicines Control Council and to the 
Ethical Committee of the University of Cape Town Medical School for 
approval prior to initiation of the study. 
2.1.1. Patients with chronic duodenal ulceration (Responders) 
2.1 .1.1. Study Location 
The study was conducted in conjunction with the staff of the 
Gastrointestinal Unit of Groote Schuur Hospital. All blood 
sampling was carried out either in the Gastrointestinal Unit 
itself or in the wards of the hospital. 
2.1.1.2. Patient selection 
Ten patients were studied in this group. They all presented to the 
Gastrointestinal Unit with signs and symptoms of peptic ulceration. 
The following exclusions were applied: 
i) patients who were considered likely to be uncooperative or 
unable to attend the clinic regularly; 
ii) patients with concurrent systemic disease; 
iii) patients with a history of previous lower oesophageal or 
gastric surgery; 
iv) patients with a history of pyloric stenosis; 
v) pregnant or lactating women; 
vi) people who had received therapy with H2-receptor blocking 
agents in the month prior to the trial; 
vii) patients with a history of recent ulcer perforation. 
The diagnosis of duodenal ulceration was established by endoscopy. 
The ulcer size was required to be equal to or larger than 3 mm 
for inclusion in the study. 
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The purpose and nature of the study was explained to the patients and 
they were asked to sign a consent form. 
The age, sex, race, weight, smoking and drinking habits and concurrent 
illnesses and medication of the patients included in the study are 
recorded in Table 2.1. Detailed case histories are to be found 
in Appendix I. (Duodenal ulcer patients-No. 1-10). 
2.1.l.3. Schedule of visits and investigations. 
Each patient was seen on three occasions over a 4 week period, and 
four returned subsequently for a fourth visit. (Figure 2.1 .). 
VISIT ONE. SINGLE-DOSE STUDY 
The diagnosis was made on endoscopic examination. 
A pentagastrin stimulated gastric secretion study was carried out in the 
Gastrointestinal Clinic. After an overnight fast a RUsch nasogastric 
tube was passed and the subject was screened by X-ray to confirm the 
position of the tube. The stomach was emptied of residual contents 
under constant pressure (3 mm/H2o). Basal secretions were collected 
at half-hourly intervals for l hour. An intramuscular injection of 
pentagastrin (6 µg/kg) was administered and gastric juice collected at 
15 minute intervals for l hour. Volumes of gastric aspirates were 
recorded and the acidity was measured by titrating l ml samples of 
gastric juice in 10 ml distilled water with O,lN NaOH (Automatic 
Titration System TTT60, Radiometer, Copenhagen, Denmark). 
The patients were then hospitalised for the duration of the pharmacokinetic 
study. After an overnight fast an indwelling intravenous catheter was 
inserted into a forearm vein. The catheter was kept patent throughout 
the sampling period by flushing with heparin in normal saline (100 units/ml). 
A 150 mg tablet of ranitidine was administered immediately prior to a 
standard hospita~ breakfast (porridge, egg, bread and jam, coffee). 
Blood samples were drawn at the following times after dosing: 





























































































































































































































































































































































































































































































































































































































































































were centrifuged as soon as possible and the separated plasma stored 
at -20°c until assayed. No further restrictions on food or fluid intake 
were made during the study period. The timing of meals was noted. 
A twenty-four hour urine collection was commenced at the time of 
dosing. 
At the end of the study therapy commenced with 150 mg ranitidine 
twice daily. 
VISIT TWO. CHECK-UP AND RECYCLING STUDY. 
All the patients were seen at the Gastrointestinal Clinic 14 days 
after the initiation of therapy. Careful note was taken of 
symptoms, response to therapy and compliance. 
Three of the patients were requested to omit their morning dose on 
this occasion. A basal blood sample was taken and the patients were 
then given breakfast after which blood samples were taken every 
10 minutes for l hour. This was done in an attempt to see if a rise 
in the levels of ranitidine could be detected which would suggest 
release of the drug from bile secreted as a result of the meal, 
followed by reabsorption of the ranitidine from the intestine 
(Veng Pedersen and Miller 1980). 
VISIT THREE. MULTIPLE-DOSE STUDY. 
Twenty-eight days after commencing therapy each patient was again 
admitted to hospital for a further 24-hour period. Again, 150 mg 
ranitidine was taken orally after an overnight fast immediately before 
breakfast. Samples were taken through an indwelling intravenous 
cannula at the following times: 
0, i, i, l, l, li, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after the 
dose. 
A 24-hour urine collection was made. 
On the day following the study the drug was withheld and a repeat 
endoscopy and acid study were done to evaluate response to therapy. 
NOTE: Prior to treatment, at the 14-day visit and at 28 days 
blood samples were taken from all the patients for the determination 
of routine haematological and biochemical parameters. The samples 
were analysed by the Chemical Pathology Department of Groote Schuur 
Hospital. 
The results are given in Appendix II (TABLES Al and A2). 
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2.1.2. Patients with chronic duodenal ulceration who did not respond 
to ranitidine therapy (Non-responders) 
The 7 patients in this group were selected from two large-scale 
clinical trial investigations. Patients who showed endoscopic 
evidence of unhealed ulcers after at least eight weeks of treatment 
with the standard dose of ranitidine (150 mg taken twice daily), 
where compliance was satisfactory, were regarded as being non-responders. 
2.1.2.1. Study location. 
Two patients were drawn from the clinical trial of ranitidine undertaken 
during 1979 and 1980 by the Gastrointestinal Unit of Groote Schuur 
Hospital. 
The remaining five patients were drawn from the clinical trial of 
ranitidine conducted in 1979 and 1980 at the Gastrointestinal Unit, 
Department of Medicine, University of Natal. 
2.1.2.2. Patient selection. 
The patients were selected on the grounds of their failed response 
to ranitidine as indicated above. Patients were excluded from further 
investigations on suspicion of malignant ulcer change, or if the 
failure of response was considered to be due to lack of compliance in 
taking the medicine. 
Details of these patients are given in Table 2.2. Case histories 
are presented in Appendix I.(Ouodenal ulcer patients - No. 11-17). 
2.1.2.3. Schedule of visits and investigations. 



































































































































































































































































































































































































occasion. R.L. underwent single- and multiple-dose pharmacokinetic 
studies as he was originally included in the group described 
in 2.1.1. above. J.S. was studied after multiple-dosing with 150 mg 
twice daily and after multiple-dosing with 300 mg daily. Acid secretion 
studies were carried out in both patients. 
The remaining patients were studied on one occasion only 1 week after 
they had been re-started on ranitidine therapy 150 mg twice daily. 
The blood samples were taken as described in 2.1 .1 .3 (multiple-dose). 
Fasting serum gastrin levels were determined in all cases in order 
to exclude the possibility of hypergastrinaemia being the cause of the 
failed response to ranitidine. The gastrin levels were measured by 
the Endocrine Laboratory of the De~artment of Medicine, University of 
Cape Town, using a CIS CEA-SORIN radioimmunoassy kit (Sorin Biomedica, 
Italy). 
2.1.3. Patients with chronic renal failure. 
2.1.3.1. Study location 
These patients all presented to the Renal Unit, Somerset Hospital, 
Green Point, Cape Town. 
2.1.3.2. Patient selection. 
All patients suffered from chronic renal failure of varying aetiology. 
A summary of patient details is given in Table 2.3. and detailed case 
histories are given in Appendix I. (Patients with renal failure - No. 1-6) 
Two groups were identified: 
Group I: Six patients with severe renal failure (creatinine clearance 
0-25 ml/min), not undergoing haemodialysis; 
Group II: Three patients with endstage renal failure (creatinine 
clearance 0-5 ml/min) treated with chronic haemodialysis. 







































































































































































































































































































































































































































































































































































































































































































































































renal function (creatinine clearance greater than 70 ml/min) served 
as the group for comparison with this renal failure group. 
Patients were not admitted to this study if they had a history of drug 
allergy or intolerance, or of liver disease. 
2.1.3.3. Schedule of visits and investigations. 
The details of the study were explained to the patients and they 
were required to sign consent forms before starting the drug 
administration. 
The Group I patients were seen on two occasions one week apart. 
Haematological and biochemical investigations were carried out prior 
to ranitidine being given, and again at the end of the week's 
treatment. The results are detailed in Appendix II (TABLES A3 and A4) 
These assays were done by the Chemical Pathology and Haematology 
Laboratories at Somerset Hospital. 
The single-dose pharmacokinetic sampling was carried out after 
administration of 150 mg ranitidine before a standard hospital 
breakfast. Blood samples were drawn through an indwelling intravenous 
catheter at the following times after dosage: 
0, ! , ! ,i , 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours. 
A 24-hour urine collection was made for the determination of total 
ranitidine excreted over that time, and for determining creatinine 
clearance. The patients were then given 75 mg ranitidine twice 
daily for 1 week (except B.S. who received 150 mg twice daily). 
Four of the patients remained in hospital for the duration of the 
study period. All patients were on a number of other drugs which 
were not altered except in the case of antacids, which were omitted 
when they were due to be taken at the same time as ranitidine on the 
day of a pharmacokinetic study. Sampling for the multiple-dose study 
was done in an identical manner to that of the single-dose (in each 
case a 75 mg dose was given, with the exception of B.S.). 
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The dialysis patients were given a single 150 mg dose of ranitidine 
3 hours prior to commencing dialysis with a Travenol dialyser (Baxter). 
Two blood samples were taken simultaneously, from the line leading 
into the dialyser and from the line leading out of the dialyser 
respectively. In two patients this was done at two different flow 
rates. Flow rate was measured by running saline through the dialyser 
and measuring the volume pumped through the machine per unit time 
at a particular setting. 
Dialysance (which is the volume of blood cleared of ranitidine each 










QB ( B. - B ) 
l 0 
Qo = -----
(B. - D) 
l 
dialysance (ml/min) 
drug conce~tration going 
out of (B
0
) the dialyser 
drug concentration in the 
blood flow (ml/min) 
(Bjaeldager et al 1980, Ma et al 1978). 
into (Bi) and coming 
dialysate 
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2.2. ANALYTICAL TECHNIQUE. 
Ranitidine hydrochloride is a potent H2- antagonist (Bradshaw et al 1980). 
A sensitive analytical method for measuring the drug in plasma and 
urine was necessary as the peak plasma concentrations were expected 
to be in the nanogram range after administration of oral therapeutically 
active doses in man. A high pressure liquid chromatographic (hplc) 
method using an untraviolet detector was developed (Carey and Martin 1979). 
This method involves extraction of the drug and an internal standard, 
AH.20480 into octanol and then a back extraction into an aqueous phase 
prior to separation by reversed phase high pressure liquid 
chromatography. 
Described below is the modified version of this method which was 
used for analysis of all samples in our pharmacokinetic studies. 
2.2.l. Materials. 
Ranitidine hydrochloride (batch no. C.314/152) and AH20480 (batch 
no. C.331/52/2) were obtained from Glaxo Group Research Ltd., Ware, 
England. 
Ranitidine hydrochloride tablets (150 mg base equivalent) (batch 
no. MR/0314, MR6241W), and the intravenous form containing 10 mg/ml 
(batch no. MR5090W) were also supplied by Glaxo Group Research 
Ltd., Ware, England. 
The following laboratory reagents with the grade and manufacturer as 
indicated were used: 
octan-1-ol, extra pure (E. Merck, Darmstadt); 
disodium hydrogen phosphate, analytical grade (E. Merck, 
Darmstadt); 
potassium dihydrogen phosphate, analytical grade (E. Merck, 
Darmstadt); 
trisodium orthophosphate, analytical grade (E. Merck, 
Darmstadt); 
methanol, analytical grade (BDH Chemicals (Ltd.), Poole, 
England); 
phosphoric acid, 88 - 93% pure (BDH Chemicals (Ltd.), Poole, 
England). 
2.2.2. Instrumentation 
The liquid chromatograph was made up of separate units. The 
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eluent was delivered by a single piston, reciprocating pump (LC3 
Chromatograph, Pye Unicam Ltd., Cambridge). Two different injection 
valves were used in the course of the study. The original fixed 
loop injection valve (Pye Unicam, Cambridge) was replaced by another 
fixed loop injection valve (Rheodyne Model 70-10, California, U.S.A.) 
as the former did not wear well with leakage being the major problem. 
A 100 µl loop was used for plasma samples and a 20 µl loop was used 
for urine assays. 
The pre-packed reversed phase columns ( µBondapak Cl8, Waters Associates 
Inc.) were 30 cm in length with an internal diameter of 3,9 mm. The 
packing material was octadecylsilane chemically bonded to 10 µm silica 
particles. The drug and internal standard were detected by a 
reference compensated variable wavelength, single beam ultraviolet 
absorbance monitor (LC3 UV Detector, Pye Unicam, Cambridge). The 
signal from the detector was fed through an integrator (Minigrator, 
Spectra Physics, California) to a linear recorder (AR 55, Pye Unicam, 
Cambridge). 
2.2.3. Extraction Procedure. 
Ranitidine hydrochloride and the internal standard,AH.20480, were 
weighed out on a digital analytical balance (Sartorius 2400, Gottingen, 
Germany). Aqueous solutions of 200 i.g/ml of ranitidine andAH 20480 
respectively were made up and stored for periods not exceeding one 
month prior to use. 
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Fresh dilutions of the above stock standards were made for each sample 
batch assayed. The internal standard, AH 20480 was diluted to 10 µ g/ml 
and an S.M.I. Micropettor (Scientific Manufacturing Industries, California) 
was used to add 25 µl of this solution to clean dry 10 ml Quickfit glass 
test tubes. The standard solutions of ranitidine appropriately diluted 
to cover the range O - 1000 ng/ml were prepared using constriction 
pipettes (Goldbrand, Brand, West Germany). Ten standards were run with 
each batch of 20 patient samples. 
One millilitre volumes of either ranitidine-free plasma in the case of 
standards or patient plasma were added to the tubes containing internal 
standard with an Oxford sampler (Oxford Laboratories). One millilitre 
of buffer (0,2M trisodium orthophosphate brought to pH 10,5 with 
phosphoric acid) was added to each tube. The tubes were agitated prior 
to the addition of 5 ml octanol with an adjustable sampler (Macroset, 
Oxford Laboratories). 
The tubes were stoppered and clamped onto a tipping table (Scientific 
Manufacturing Company, Milnerton, South Africa) and mixed at a rate 
of 100 tips/min for 20 minutes and at an angle which ensured complete 
mixing. They were then centrifuged at 2000 r.p.m. (Sorvall RC 3B 
Centrifuge, Du Pont, Connecticut). 
Approximately 4,5 ml of the octanol layer were transferred to glass tubes 
containing 0,5 ml of O,lM phosphate buffer (pH 6,0) for back extraction. 
The tubes were again mixed on the tipping table for 20 minutes and then 
centrifuged for a further 10-minute period. The buffer layer was 
carefully removed using a pasteur pipette and placed in clean glass 
tubes. 
night. 
The samples were normally left at room temperature over-
Urine samples were extracted in a similar manner except that a 
dilution of 1:5 or 1:10 with distilled water was made before extraction 
and the ca 1 ibration curve was set up over the range O - 7 µ g/ml. 
2.2.4. Chromatography. 
The eluent consisted of 58% methanol and 42% O,lM phosphate buffer, 
pH 7 ,0. In order to eliminate particulate matter and to de-gas the 
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eluent it was filtered through a 0, 5 i.i m mill ipore filter (Millipore Corporation, 
Massachusetts) under vacuum. The eluent was delivered to the column at a 
flow rate of 1,5 ml/min. The column was maintained at room temperature. 
Absorbance was measured at a wavelength of 318 nm with the integrator set 
at maximum sensitivity. In the case of plasma 100 i.il samples were 
injected and for urine 20 i.il samples were injected onto the column. 
The retention times for ranitidine andAH20480 were approximately 300 and 
400 seconds respectively. Figure 2.2 shows a chromatogram of a plasma 
standard containing 104 ng/ml of ranitidine and internal standard.and 
Figure 2.3. shows the chromatogram of a patient plasma sample with an 
estimated ranitidine concentration of 204 ng/ml. It is clear that the 
peaks of interest are adequately separated and that the peak heights can 
easily be measured. Figure 2.4 is the chromatogram of a plasma sample 
from a patient with renal failure. In addition to ranitidine (peak A) 
and AH 20480 (peak B) there is a peak (peak C) with a retention time shorter 
than ranitidine. 
quant ita ted. 
This was identified as a metabolite but could not be 
The chromatogram of a urine extract from a patient with renal failure is 
shown in Figure 2.5. The metabolite peak C, is again apparent. 
The ranitidine peak (A) and AH 20480 (B) were well resolved and there was 
no interference from other drugs or endogenous material in the urine. 
Prior to the analysis of patients• samples validation of the methods for 
urine and for plasma were carried out to determine sensitivity linearity 
and precision. 
In the case of the plasma validation,5 spiked samples at 5 different 
concentrations were assayed (Table 2.1.). It can be seen from Figure 2.6 
that the relationship between the peak height ratio of ranitidine and 
internal standard to the concentration is linear. The best straight 
line through the points was obtained by linear regression on a 
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Figure 2.2. Chromatogram of a standard plasma sample 
spiked with 104 ng/ml ranitidine (peak Al and internal 
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Figure 2.3 Chromatogram of plasma extract containing 204ng/ml ranitidine from 
patient with duodenal ulceration taken 25 minutes after intravenous 
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10 8 6 4 2 Ominutes 
Figure 2.5. Chromatogram of a urine extract from a patient with renal 
failure.The sample contained 2.5 µg/ml of ranitidine after a 5-fold dilution. 
Peak A ranitidine, peak B AH 20480, peak C ranitidine metabolite. 
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Expected Number of Mean peak Standard Coefficient Observed 
concentration determinations height deviation of concentra-
( ng/ml) ratio variation tion 
(%) ( ng/ml) 
0,0 5 0,000 0,000 0,0 0,4 
21 ,4 5 0,091 0,006 6,7 24,2 
107, 1 5 0,396 0,018 4,4 103 ,6 
535,5 5 2,044 0,034 1 , 6 533,1 
749,7 5 2,889 0 ,041 1 ,4 753 ,4 
1071 , 0 5 4,104 0,062 1 , 5 1070,0 
TABLE 2.1. Validation results for the extraction of ranitidine from plasma. 
The linear regression equation had a slope of 0,0038 with an axis intercept 
of -0,0019 and a correlation coefficient, r=0,9998 
Expected 
concentration 






Number of Mean peak 
determinations height 
ratio 
4 0 ,000 
4 0, 249 
4 0,498 
4 1 , 259 


























TABLE 2.2. Validation results for the extraction of ranitidine from urine. 
Linear regression analysis gave a slope of 0,235 with an axis intercept 



































































































































































































Ranitidine Concentration IJJg/mll 
Figure 2. 7 Validation curve for ranitidine extracted 
from urine from 5 sets of 4 standards. 
!Regression coefficient r =0,99981 
Texas Instruments 59 calculator giving the equation 
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y = 0,0038 x - 0,0019 with a regression coefficient r = 0,9998. 
The lower limit of detection was taken as 20 ng/ml as the coefficient 
of variation for concentrations lower than this exceeded 10% due to 
difficulty in measuring small peak heights. 
The results for the validation of the method for urine are given in 
Table 2.2. The regression equation was y = 0,2350 x - 0,0045 with a 
regression coefficient, r =0,9998 showing the linearity of this ratio 
of peak heights of ranitidine and internal standard to concentration 
over the range l - 7.5 µg/ml. The coefficient of variation ranged from 
2,9% at a concentration of l µg/ml to 0,7% at a concentration of 
7,5 µg/ml. 
At least 50% of patients• plasma samples were re-assayed on a separate 
occasion. If the two assays did not agree to within 10% the samples were 
assayed a third time. 
2.2.5. Discussion. 
The differences between the published method (Carey and Martin 1979) 
and the one described above are that our system was not automated, the 
column was at room temperature instead of 4o0c and the buffer used in 
the initial extraction was of pH 10,5 and not pH 9,0. 
Peak height ratios were used instead of peak areas. The reason for this 
was that without regulating column temperature there was no control 
over the separation of the ranitidine peak (A) and the negative peak (D) 
(Figure 2.2) which made setting up of the integrator difficult. 
The negative peak was caused by solvent mismatching. 
It was impossible to quantitate metabolites simultaneously with ranitidine 
as the desmethyl and S-oxide metabolites could not be resolved from each 
other while the N-oxide of ranitidine had a retention time coinciding with 
the solvent front under our chromatographic conditions. 
41 
2.3. PHARMACOKINETIC ANALYSIS 
2.3.l. Computer fitting of data 
The nonlinear least squares regression programme NONLIN (Metzler, C.M., 
Upjohn Company, Kalamazoo, Michigan 490001) was used for the fitting 
of plasma concentration-time data and for the estimation of pharmacokinetic 
parameters. 
Rough estimates for the computer fitting of the data were obtained by 
the method of residuals (Gibaldi and Perrier 1975). 
The oral data were fitted to both a one-and two-compartment model. 
No weighting functions were used. Akaike's Information Criterion 
(AIC) was used to determine the least number of exponential terms which 
best described the data. (Yamaoka et al 1978). The equation with 
the lowest AIC was taken as the simplest representation of the data. 
The following formula was used to calculate AIC: 
AIC = N ln Re+2p (2) 
where N = number of experimental points 
Re = residual sum of squares 
p = number of parameters in the estimated model 
ln = natural logarithm 
The notations used in the regression equations are 
cP = concentration in plasma at time t 
FD/V = availability term made up of 
F = fraction of the dose absorbed 
D = dose 
V = apparent volume of distribution 
ka = absorption rate constant 
t . lag = lag time to start of absorption 
k21 and k12 = rate constants for transfer of drug into and out of 
the peripheral compartment 
kel = apparent first order elimination rate constant 
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k10 = apparent first order elimination rate constant 
from central compartment 
c0 = residual concentration present at time zero 
of multiple dosing 
s = disposition rate constant (for a one compartment model 
ke1=k10= s ) 
a = distribution rate constant 
The regression equations for the single dose situation are as follows: 
( 3) 
* where t = t-tlag 
for an oral one-compartment open model and 
[
(k21 _k) -kt* (k21 -s) 
Cp=(FD/V)ka (a -k )(s -k) e a + (ka-a )(s 
a a 
- a t* ( k -S ) - S tj 
e + 21 e 









far an oral first order input two-compartment model. 
In the multiple-dose situation the models used do not assume that the 
patient is in steady state but the residual concentration (C0) due to 
previous dose present in plasma compartment at the time of the dose 
administration was taken into account by using the principle of 
superposition, assuming linear kinetics. 
The regression equations for multiple oral doses are 
(5) 
for a one-compartment model and 
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* ( k -k ) -k t* ( k21 - a. ) - a. t C p = ( FD/ V ) k a +,------,-21 ............. a_,---,- e a + e 
a -k S -k ( ka- a )( S - a ) a a 
( k21 - s ) - s t* 
+ (ka-s )( a.-s) e 
L ( k21 - a ) e - a t + ( k21 - 6 ) _ e - S t ] 
l(s-a) (a-S) 
LJ_) e- at + 1 e -s t] 
[(s-a.) (a.-s) 
(6) 
for the first order absorption two-compartment model. 
The plasma concentration-time data obtained after intravenous dosing were 
fitted to the standard two-compartment model without weighting. The 
equation describing the model is 
[ 
( a - k21 ) e - a t + 
( a -S ) 
( k21 - s ) 
( a - S ) 
e-B t] (7) 
where Ve = apparent volume of distribution of the central compartment 
These equations were all derived by standard means (Veng Pedersen 1978). 
2.3.2. Theoretical plasma concentration-time curves 
The pharmacokinetic parameters estimated by computer fitting were used to 
construct the theoretical plasma concentration-time curves. These figures 
were plotted on a Hewlett-Packard 9872A plotter connected to a Hewlett-
Packard 9825A calculator. 
2.3.3. Biological half-life(t1 ) 
2 
The half-time of a drug which is eliminated by first-order processes 
is a constant which is independent of initial concentration and dose. 
The overall elimination rate constants (or kel = sin a one-compartment 
model) was used to calculate the half-life: 




2.3.4. Area under the plasma level-time curve (AUC). 
The trapezoidal rule, an approximate integration formula, was used 
to determine the area under the plasma level-time curves in the oral 
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single and multiple-dose studies from time Oto 12 hours. 
Since sampling intervals were not constant the following general 
formula was used 
tn n-1 t. , -t. J ¢ (t)dt " 1+ 1 c. + Ci+ 1) (9) = L. i=O 2 l ta 
(Gibaldi and Perrier 1975) 
This method was chosen because of its simplicity but at the same time 
it was recognised that it is not the most accurate means of measuring 
AUC. (Chiou 1978, Yen and Kwan 1978). 
In the case of the ranitidine study the underestimation in the relatively 
short absorption phase is balanced to a certain extent by the overestimation 
in the post-absorption phase. The error in the post-absorption phase 
is approximately 4% since in our case the ratio of the longest sampling 
interval (2 hours) to the half-life is approximately 1 (Chiou 1978). 
This was considered acceptable as AUC is the end point measurement and 
all data have similar sampling times and shapes. 
The AUC for single-dose studies was calcuated in two parts. The 
trapezoidal rule as described above was used to calculate AUC from 
0 to 12 hours. 
the formula 
The AUC from 12 hours to infinity was calculated using 
B 
where c. = concentration at 12 hours 
12· 
B = disposition rate constant 
The total AUC for the intravenous data was calculated using the 
formula 
co J C(t)dt = AUC0_ 00 = D + 
0 
(Wagner 1975) 
2.3.5. Apparent volume of distribution 
(10) 
( 11) 
The apparent volume of distribution of a drug in a given compartment of a 
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model is the constant (expressed as a volume) which relates the 
concentration in that compartment to the total amount of drug in the 
compartment. 
In the two-compartment intravenous model the volume of distribution 
of the central compartment (Ve) was estimated from the least squares 
regression analysis. V relates the plasma concentration (C) to the 
C 
total amount of drug in the central compartment (Xe). Hence 
Xe = V / ( 12) 
The apparent volume of distribution of a drug in the whole body (VB) can 
be related to the plasma concentration (C) in the post-distributive phase 
since 
VB = X/C (13) 









VB was therefore calculated- from the computer estimates of Vc,klO' and S. 
(Gibaldi and Perrier 1975). 
This volume of distribution (VB) has also been called the volume of 
distribution area (V ) as it can be calculated from darea 
Xo (15) 
B .( Cdt 
where x0= dose administered 
and { Cdt = total area under the plasma concentration-time curve 
from zero to infinity 
The volume of distribution normally quoted in the literature is the 
volume of distribution (Vdext). By definition 





This was calculated from the computer derived parameters a, B , K21 and Ve 
The fourth volume of distribution commonly used is the volume of 
distributionsteadystate (Vdss). This was calculated by 
Vdss = Vc(l+K12) (17) 
K21 
These volumes of distribution were calculated using the intravenous study 
data. 
The relative magnitudes of the volumes of distribution are 
(wagner 1975) 
2.3.6. Clearance 
The total clearance of a drug (C) from the body is a constant since it 
is the product of two constants in any given patient 
(18) 
It is also equal to the clearance from the central compartment 
C = Ve klO and thus (19) 
XO 
C =-----_("00 Cdt (20) 
(Gibaldi and Perrier 1975) 
Clearance values were calculated from the above equations for intravenous 
data. 
From equation (20) it is clear that C is inversely proportional to the 
area under the curve (AUC). AUC was used as an index of clearance 
in the oral dosage situation where C cannot be calculated, to compare 
clearance in patients with normal renal function with those with 
impaired renal function. 
2.3.7. Bioavailability. 
The efficiency of absorption (F) assuming no significant first-pass 





where the AUC was measured as described above. 
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(21) 
2.4. STATISTICAL ANALYSIS 
The Wilcoxon matched-pairs signed-ranks test was used to test for 
differences between pharmacokinetic parameters obtained in the 
same patient after single and multiple dosage (Siegel 1956). 
a< 0,05 was taken as the level of significance for a two-tailed 
test. 
The Mann-Whitney U test was used to test the differences between 
responders and non-responders and between patients with normal renal 
function and with renal failure. a< 0,05 for a two-tailed test 
was decided on as being significant (Siegel 1956). 
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3. RESULTS. 
3. 1. CHRONIC DUODENAL ULCER PATIENTS - RESPONDERS. 
The ten patients in this group responded to a 28 days' course of 
ranitidine, at the end of which they had endoscopic evidence of ulcer 
healing. The endoscopy reports are summarized in Table 3. 1. The results 
of the acid studies prior to treatment and at the end of the 28 days' 
treatment are given in Table 3.2. 
The mean basal acid output (BAO) pre-treatment was 4,4 meq/h (range 0,0-
9,1) and pentagastrin stimulated maximum acid output (MAO) pre-treatment 
was 27,2 meq/h (range 16,2-39,1). After 28 days' treatment, the mean BAO 
was 5,7 meq/h (range 2,0-11 ,7) and the MAO was 24,0 meq/h (range 14,6-
36 ,5). 
The post-treatment levels did not differ significantly from pre-treatment 
values. 
3. 1. 1. Oral single- and multiple-dose studies. 
Plasma ranitidine concentrations after administration of a single 150 mg 
tablet and the concentrations after multiple dosing are shown in Tables 
3.3 and 3.4 respectively. 
The maximum and minimum concentrations which are discussed below are 
taken directly from the concentration-time data. 
The median maximum plasma concentration (Cmax) after a single-dose was 
365 ng/ml which was achieved at a median time of 2 hours (Table 3.5). 
In the case of multiple dosing the time taken to reach Cmax was shorter 
in most patients but the median value of 1 hour did not differ significantly 
from the median value after single dosing (p > 0,05). The median Cmax after 
multiple dosing was 562 ng/ml and this was significantly greater than Cmax 
after single-dosing (p <0,05). Even after the multiple dosing Cmax was 
corrected for the residual concentration present at time zero (Cmin(O)) 
the difference from single-dose Cmax remained significant (p <0,05). 
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Table 3. l. Summary of endoscopy reports of responders. 
Initials Pre-treatment 
J.H. Oesophagus and stomach normal. 
Defonned duodenal cap. 
Single duodenal ulcer, 
superior superficial 0,8 cm 
diameter. 
T.W. Normal oesophagus. Gastritis. 
Pylorus deformed, wide. 
Small shallow ulcer on 
superior aspect of duodenal 
cap. 








Erosive duodenitis. Single 
ulcer in duodenum, l x 0,6 
cm in size. 
Fundal erosions with mild 
gastritis. Posterior-
inferior ulcer, 0,5 cm in 
diameter in duodenum. 
Oesophagus and stomach normal. 
0,4 cm duodenal ulcer on 
base of anterior wall at 
beginning of second part. 
Pyloric narrowing. 0,4 x 
0,8 cm oral duodenal ulcer 
on anterior aspect of lesser 
curve. 
Blood stained fluid++. 
Small blood clot in fundus. 
Multiple ulcers in duodenum. 
Ulcer l ,0 cm diameter on 
greater curve of duodenum. 
Deformed antrum. 0,8 cm 
diameter duodenal ulcer. 
Deformed duodenal cap. 
Circumferential swollen fold 
with duodenal ulcer 0,6 x 
0,4 cm. 
Duodenitis. Single duodenal 
0,3 cm diameter ulcer. ' 
Post-treatment 
Duodenitis of anterior aspect of 
greater curve of duodenum. 
Linear scar in duodenum. 
Duodenal diverticulum noted. Small 
linear scar on anterior wall of 
duodenum. 
Erosions, duodenitis and scar. 
Scar just inside cap on floor of 
duodenum. 
Duodenitis and erosions at site of 
old ulcer. 
Duodenal erosions. 
Complete healing of target duodenal 
ulcer with two peripheral erosions. 
Anterior ulcer with large central 
erosion. 
Gastric erosions, due to nasogastric 
tube. Duodenitis, swollen mucosal 
folds and scarring. 
Duodenum: pit and erosions. 
Healed duodenal ulcer. 
Healed duodenal ulcer with a 
deformed duodenal cap. 
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Table 3.2. Basal acid output (BAO) and pentagastrin-stimulated 
maximum acid output (MAO) pre- and post-treatment (28 days) in duodenal 
ulcer patients who responded to ranitidine. 
PRE-TREATMENT POST-TREATMENT (28 DAYS) 
Initials BAO MAO BAO MAO 
meq/h meq/h meq/h meq/h 
J.H. 2 ,6 16,2 7,2 16,4 
T.W. 2,4 26,4 6,7 14 ,6 
A.d.S. 6,7 27,9 11 , 7 26,7 
M.S. 3,2 25,5 8,0 23,5 
S.M. 9, l 39, l 4,2 36,5 
O.F. 5,8 25,6 3, l 21 ,6 
P.d.J. 7,2 27,6 2,4 27,2 
W.M. 0,0 22,9 2,0 25,4 
A.O. 2,7 24,2 
0. S .. 4,7 36,4 
mean 4,4 27,2 5,7 24,0 
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Table 3.5. The maximum concentration (Cmax) and the time taken to 
reach Cmax (tmax) after single- and multiple dosing; and the Cmax 
corrected for residual concentrations at zero time (Cmin(O)) after 
multiple dosing. 
SINGLE DOSE MULTIPLE DOSE 
55 
Initials Cmax tmax Cmax tmax Cmax-Cmin(O) 
(ng/ml) (h) (ng/ml) (h) (ng/ml) 
J.H. 252 3,0 579 0,5 544 
T.W. 354 2,25 545 l , 0 497 
A.d.S. 347 l , 5 803 l ,5 788 
M.S. 451 2,0 819 l , 0 811 
S.M. 382 2,0 526 l , 5 495 
D.F. 358 l , 5 326 l , 0 292 
P.d.J. 444 2,0 824 1 ,0 714 
W.M. 540 l ,5 313 2,0 297 
A.O. 207 l , 0 422 2,0 392 
D.S. 340 2,0 692 1 ,0 546 
mean 368 l , 9 585 l ,25 538 
median 356 2,0 562* 1 , 0 521* 
range 207-540 l ,0-3,0 313-824 0,5-2,0 292-811 
* p <0,05 
The median minimum concentrations ( Cm i n ( 1 2 )} at l 2 hours post-dosing in 
the single- and multiple-dose studies were 35 and 30 ng/ml respectively 
(Table 3.6). These values were not significantly different (p >0,05). 
When the Cmin values for multiple dosing at zero time (Cmin(O)) and 
12 hours post-dosing (Cmin(12)) were compared there was no significant 
difference (p >0,05). 
Table 3.6. The minimum concentrations (Cmin) at 12 hours post-
dosing after single dosing and at zero time and 12 hours post-dosing 
after multiple-dosing. 
SINGLE DOSE MULTIPLE DOSE 
Initials Cmin(12) Cmin(O) Cmin(12) 
(ng/ml) (ng/ml) (ng/ml) 
J.H. 36 35 32 
T. w. 30 48 36 
A.d.S. 33 15 16 
M.S. 48 8 38 
S. M. 24 31 20 
D.F. 23 34 17 
P.d.J. 37 110 35 
W.M. 12 16 18 
A.O. 38 30 28 
D.S. 40 146 42 
mean 32 47 28 
median 35 33 30 
range 12-48 8-146 16-42 
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The concentration-time data for single- and multiple-dosing for each 
patient were fitted to both a one-compartment and a two-compartment model. 
Akaike's Information Criterion (AIC) was calculated in order to choose 
the simplest model fitting the data (Table 3.7.). One patient exhibited 
two-compartment model characteristics after single dosing, and two patients 
did so after multiple dosing. After multiple-dose model fitting, two 
patients (S.M. and D.S.) had the same AIC value for both models, therefore 
the one-compartment model was chosen. 




1 Compartment 2 Compartments Compartment 2 Compartments 
J.H. 117* 121 162 114* 
T.W. 106* 117 132* 135 
A.d.S. 110* 112 152* 166 
M.S. 122* 126 130* 146 
S.M. 120* 124 143* 143 
D.F. 134 110* 121* 131 
P.d.J. 131* 141 129 118* 
W.M. 122* 126 122* 137 
A.O. 111* 123 141* 156 
D.S. 96* 125 133* 133 
* The model chosen 
The pharmacoki neti c parameters generated from the computer fitting of 
the concentration-time data were: the absorption rate constant (ka); 
the bioavailability term (FD/V); lag time to start of absorption (tlag); 
the disposition rate constant (kel or S) and where a two-compartment 
model was chosen, the distribution rate constant (a). 
Tables 3.8. and 3.9. show these parameters for single- and multiple-doses 
respectively. 
Table 3.8. Computer generated pharmacokinetic parameters after 
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range 0,37-3,26 0,0-33,8 229,0-1 381,4 0,19-0,82 




Table 3.9. Computer generated phannacokinetic parameters after multiple 








































2, 39 13 ,2 
0,70-11 ,05 0,0-28,2 
FD/V 
(ng/ml) 
3 381 , 1 
523,3 




























Absorption was rapid with median ka values of 1 ,31 h-l and 2,39 h-l for 
for single and multiple dosing respectively. These values were not 
significantly different. The respective median lag times to start of 
absorption were 19,3 min and 13,2 min. Again there was no significant 
difference between single and multiple dosing. The FD/V values were on 
the margin of being significantly larger after multiple dosing (p = 0,05) 
than after single dosing, with median values of 850,9 and 549,5 ng/ml 
respectively. There was no significant difference in the disposition 
rate constants and the median values were identical (0,31 h- 1). The 
value of a(0,30 h-l) for patient D.F. after single dosing was used in 
the calculation of the median disposition rate constant as this value 
correlated better with the elimination rates in other patients than the 
-1 B value of 0,01 h . This small B value appears to be due to slow 
release of ranitidine from a deep body compartment. 
The median half-lives after both single and multiple dosing were 135 
minutes (Table 3. 10). There is thus no significant difference in the 
disappearance of the drug from plasma after single or multiple dosage. 
The half-lives were calculated from kel or B values generated by the 
computer. 
The theoretical plasma concentration-time curves derived from the computer 
fits of data are shown in Figures 3. l - 3. 10. Each figure, showing the 
theoretical curves for single- and multiple-dosing with their respective 
regression coefficients as well as the observed concentrations after 
single and multiple doses, represents a single patient. The data for one 
patient (A.O.) fitted poorly to one- and two-compartment models for both 
single- and multiple-doses (Figure 3.9.). 
recycling model may fit the data better. 
Another model such as a 
TABLE 3. 10. Plasma ranitidine half-lives (t 1 ) after single and 
2 
multiple doses in responders. 
Initials Single dose Multiple dose 
tl (min) tl (min) 
2 2 
J.H. 189 139 
T.W. 130 154 
A.d.S. 116 62 
M.S. 181 130 
S.M. 51 52 
D.F. 139 139 
P.d.J. 130 160 
W.M. 104 139 
A.O. 219 99 
D.S. 154 122 
mean 141 120 
median 135 135 
range 51-219 52-160 
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TABLE 3.11. The areas under the plasma ranitidine concentration-
time curves (AUC) for single- and multiple-dose studies in responders. 
Single dose Multiple dose 
Initials AUC AUC 
(ng/ml. hr) (ng/ml. hr) 
J.H. l 700 2 138 
T.W. l 983 2 036 
A.d.S. l 616 2 486 
M.S. 2 444 3 074 
S.M. l 738 2 078 
D.F. l 700 l 467 
P.d.J. 2 688 2 989 
W.M. l 845 l 458 
A.O. l 304 l 695 
D.S. l 950 2 601 
mean l 897 2 202 
median l 844 2 108* 
range l 304-2 688 l 458-3 074 
* p <0 ,05 vs single-do~e 
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The areas under the curve (AUC) are shown in Table 3. 11. The AUC after 
multiple-dosage is significantly larger than after single dosage (p <0,05) 
with median values of 2 108 and l 844 ng/ml respectively. 
The total amounts of ranitidine excreted in urine in the 24 hours 
following a single dose, expressed as a percentage of the dose administered 
are shown in Table 3. 12, together with the uncorrected creatinine 
clearance values determined from the same urine sample and the 
creatinine clearances calculated from serum creatinine corrected for 
age, sex and weight (Lot and Hayton 1978). 
TABLE 3.12. The amount of ranitidine excreted unchanged in the urine 
in 24 hours after a single 150 mg ranitidine dose expressed as a 
percentage of dose, uncorrected creatinine clearance calculated from 
the same urine sample and creatinine clearance estimated from serum 
creatinine concentration. 
% Unchanged Creatinine Estimated 
Initials ranitidine in clearance creatinine clearance 
24 hr. urine (ml/min) (ml/min) 
J.H. 26 106 
T.W. 26 69 
A.d.S. 35 135 109 
M.S. 15 73 79 
S.M. 80 
D.F. 21 71 106 
P.d.J. 38 65 77 
W.M. 48 132 125 
A.O. 28 102 93 
D.S. 23 68 109 
mean 29 95 
median 26 100 
range 15-48 69-125 
Key: incomplete urine collection 
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TABLE 3.13. The percentage of unchanged ranitidine excreted in the 
urine in the 24 hours after multiple-dosing, together with the 
uncorrected creatinine clearance calculated from the same urine sample 









































Key: - incomplete urine collection. 















There was no significant difference in the percentage of ranitidine 
excreted in 24 hours after multiple dosing when compared to single-
dosing (p >0,05). The creatinine clearances had not changed significantly 
after multiple-dosing from those obtained at the time of the single-dose 
study. The completeness of the 24-hour urine collection for the multiple-
dose study in one patient (W.M.) was suspect as the creatinine clearances 




3.1.2. Recycling study 
The plasma concentrations measured at 10 minute intervals after a 
standard hospital breakfast when the morning ranitidine tablet was 
withheld, are given in Table 3.14. These concentrations were close 
to the lower limit of the reliable assay range. The apparent slight 
increase in the levels in patient D.F. was possibly due to assay 
error. This did not support a theory of recycling and reabsorption 
of ranitidine from the previous evenings' dose in relation to breakfast 
in tnese three patients. 
TABLE 3. 14. Plasma concentrations (ng/ml) in three patients taken 
































3. l. 3. Intravenous study. 
four responders and one non-responder were given 20 mg ranitidine intra-
venously over 2 minutes as a 1 mg/ml solution in normal saline. The 
concentration-time data are given in Table 3. 15. The time was taken 
from the end of the infusion period. The data when fitted to a two-
compartment model using the NONLIN computer programme gave regression 
coefficients varying from 0,997-0,999, which made trial of another model 
unnecessary. 
The computed pharmacokinetic parameters appear in Table 3. 16. There is 
a 3-fold variation in the rate constants of transfer into and out of the 
peripheral compartment (k12 and k21 ) as well as in k10 which is the 
elimination rate constant from the central compartment. The apparent 
volume of distribution of the central compartment (Ve) ranged from 10,5 
to 28,4£ which was not improved when corrected for weight (range 190,4 
to 436,9 ml/kg). The distribution rate constant (a) and the disposition 
rate constant (B), moreover, varied 2,6-fold and 2,3-fold respectively. 
The computer generated pharmacokinetic parameters were used to 
calculate AUCO-co' Vdext' Vdarea' Vdss' C, t~a and t~B (Table 3.17). 
The variation was greatest for the AUC and clearance. 
There was no apparent correlation between V , AUC, Vd and the weights 
C SS 
of the patients. There was, however, a fairly strong correlation 
2 r- 2 between Vdext and age (r =0,90, p <O,~area and age (r =0.89, p <0,01) 
and Vdss and age (r2=0,76, p <0,05) despite the narrow age range of the 
five patients. The half-life (t; ) was not age-related (r2=0,002). 
Half-life could not be correlated with the creatinine clearance 
(calculated from serum creatinine) (r2=0,45, p >0,05) but total plasma 
clearance showed a significant correlation with creatinine (r2=0,71, 





















































































































































































































































































































































































































TABLE 3. 16. Computer generated pharmacokinetic parameters from 
fitting of a two-compartment model to intravenous data. 
k12 k21 klO V V a s 
Initials C C 
(h-1) ( h -1 ) (h-1) ( ,Q,) (ml/kg) ( h - l ) ( h - l ) 
P.d.J. 3 ,61 1 ,43 1,48 10,5 210,0 6,18 0 ,34 
W.M. 4,77 3,56 2,02 28,4 436,9 9 ,61 0,75 
S.M. 6,79 3,08 2,61 13,0 228,0 11 ,80 0 ,68 
D.S. 8,69 3,51 3 ,28 17 ,9 190,4 14, 70 0,78 
R.L. 2,97 l , 11 l ,89 20,3 302,9 5,59 0,38 
median 4,77 3 ,08 2,02 17 ,9 228,0 9,61 0 ,68 
range 2 ,97- l , 11- 1,48- 10 ,5- 190,4- 5,59- 0,34-
8,69 3,56 3,28 28,4 436,9 14, 70 0,78 
76 
TABLE 3. 17. Calculated pharmacokinetic parameters after intravenous 
administration of 20 mg ranitidine. 
AUC vdext Vdarea vdss C tl t~B Initials 2Ci. (ng/ml .h) ( Q,) ( Q,) ( Q,) (ml/min) (min) (min) 
P.d.J. 1 288 56,3 45, 7 37,0 258,9 6,7 122,3 
W.M. 348 89,5 76 ,6 66,5 957,0 4,3 55,4 
S.M. 590 60 ,2 49 ,9 41. 7 565,5 3,5 61 , l 
D.S. 341 75,0 75,3 62,2 978,9 2,8 53,3 
R.L. 523 144,9 100,7 74,6 637,8 7,4 109,4 
median 523 75,0 75 ,3 62,2 637,8 4,3 61 , l 
range 341- 56,3- 45, 7- 37,0- 258,9- 2 ,8- 53,3-
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Figure 3.11 Relationship between volume of distribution steady 
state I Vdss I and age; total ranitidine clearance IC I and 
creatmine clearance I Ccr ). 
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TABLE 3. 19. Bioavailability after a single oral 150 mg ranitidine 
tablet and the dosage and areas under the curve (AUC) used to calculate 
bi oavai l ability. 
Patient AUC oral Dose oral AUC. lV Doseiv Bi oava il ability 
(ng/ml-hr) (mg) (ng/ml-hr) (mg) (%) 
P.d.J. 2 688 150 l 288 20 28 
W.M. l 845 150 348 20 71 
S.M. l 738 150 590 20 39 
D.S. l 950 150 341 20 76 
R.L. l 540 150 523 20 39 
The bioavailability after a single 150 mg ranitidine calculated by 
the AUC method was extremely variable, ranging from 28% to 76% with 
a median value of 39% (mean 51%) (Table 3.18). 
The theoretical plasma concentration-time curves for the intravenous 
data are given in Figures 3.12-3. 16. 
Complete 24-hour urine collections were made in only two patients 
(P.d.J. and D.S.) who excreted 13% and 7% of the dose respectively 
as unchanged ranitidine in the 24 hours following the dose. 
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3.2. PATIENTS WITH CHRONIC DUODENAL ULCERATION - NON-RESPONDERS. 
This group of patients had endoscopic evidence of unhealed duodenal 
ulcers at the end of at least 8 weeks' treatment with ranitidine. 
Endoscopy reports are included in the case histories in Appendix I. 
These patients were all studied after multiple dosing and one patient 
(R.L.) had a single-dose study and another (J.S.) an increased dosage 
multiple-dose study in addition. The plasma concentration-time data 
are given in Table 3.20 and the data for the additional studies in 
Table 3.21. 
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Results of basal acid output (BAO) and pentagastrin stimulated maximum 
acid output (MAO) for 6 of these patients are given in Table 3.22, 
together with the fasting serum gastrin taken at the time of the 
pharmacokinetic study. The fasting serum gastrin levels ranged from 
12,2-67,8 pg/ml, all of which were well within the normal range of 
0-100 pg/ml. The acid studies were carried out in 4 patients just prior 
to the start of the ranitidine trial while J.S. had an acid study on being 
classified as a non-responder 12 weeks after starting the ranitidine trial. 
The only gastric acid levels available on P.M. were carried out a year 
after the study. Three patients had BAO and MAO well above the range 
for responders. 
The median values for Cmax, tmax, Cmin (0) and Cmin (12) were 599 ng/ml, 
1 ,5 h, 48 ng/ml and 44 ng/ml (Table 3.23 with corresponding values for 
responders given in brackets). There were no significant differences 
between the responders and the non-responders. 

























































































































































































































































































































































































































































































































































































































































































TABLE 3.22. Basal acid output (BAO) and pentagastrin stimulated 
maximum acid output (MAO) and fasting serum gastrin levels for non-
responders. 
Initials BAO MAO Fasting ga
strin 
(meq/h) (meq/h) (pg/ml) 
J.S. l 16 ,5 45,9 12,2 
R. L. 2 22,5 59,6 27 ,9 
D.S. 67 ,8 
D.M. 2 29,4 93,9 44,7 
S.S. 2 l ,6 33,7 66,5 
P.P. 2 4,4 30,4 53,7 
P.M. 3 4,4 25,3 29,2 
range 1,6-29,4 25,3-93,9 12,2-67,8 
(0,0-9,l) (16,2-39,l) 
Key: Acids measured after 8 weeks' ranitidine 
2 Acids measured prior to ranitidine trial 
3 Acids measured l year after trial 
( ) Range for responders 
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TABLE 3.23. The maximum concentrations (Cmax), time to reach Cmax 
(tmax), minimum concentration at zero time (Cmin(O)) and at 12 hours 
post-dosing (Cmin(l2)) for non-responders. 
Initials Cmax tmax Cmin(O) Cmin(l2) (ng/ml) ( h) (ng/ml) (ng/ml) 
J.S. 243 0,5 21 20 
R. L. 573 0,75 21 16 
D.S. 779 1,5 196 58 
D.M. 599 1,5 48 44 
S.S. 611 1,5 58 62 
P.P. 426 2,0 56 35 
P.M. 735 1,0 7 62 
median 599 1,5 48 44 
(562) (1,0) {33) {30) 
range 243-779 0,5-2,0 7-196 16-62 
(313-824) (0,5-2,0) (8-146) (16-42) 
( ) values for responders 
90 
Cmax = 420 ng/ml, tmax = 0,3 h, Cmin(l2) = 33 ng/ml. This patient had 
very rapid absorption with other parameters similar to responders. 
From Table 3.23 it can be seen that Cmax for patient J.S. was 243 ng/ml, 
the lowest value observed in any patient. After multiple-dosing with 
300 mg twice daily Cmax of the same patient was increased to 403 ng/ml 
at 2 hours; the Cmin(O) was 34 ng/ml and the Cmin(l2) 74 ng/ml. 
From Table 3.24 it can be seen that in all cases except one (R.L.), the 
one compartment model yielded the lower AIC value. One patient (R.L.) 
exhibited two compartment characteristics after single- and multiple-
dosing. The same patient was also studied after administration of 
intravenous ranitidine (see Section 3. 1.3). 
TABLE 3. 24. Akaike 1 s Infonnation Criteria (AIC) for one- and two-
compartment model fittings for non-responders. 
Initials l Compartment 
J.S. 134,l* 
J.S. l 120, 7* 
R.L. 130, l 
R.L. 2 136, l 
D.S. 152,7* 
D.M. 139, 7* 
S.S. 119,5* 
p. p. 125,0* 
P.M. 144 ,2* 
* Model chosen for analysis 
l Multiple-dose 300 mg 
2 Single-dose 150 mg 











TABLE 3.25. Computer generated multiple-dose pharmacokinetic 






























( 13 ,2) 
1 , 3 4- 9 , 5 2 1 4 , 0- 3 7 , 4 
(0,70-11,05) (0,0-28,2) 
Key: ++ p <0,002 

























The computer generated pharmacokinetic parameters for the chosen model 
are given in Table 3.25. When compared to the parameters in responders, 
no significant differences were found in non-responders except in the 
disposition rate constant (kel) which was smaller in non-responders than 
responders with median values of 0,24 h-l and 0,31 h-l respectively 
(p <0,002). Non-responders had a longer median t 1 of 173 minutes compared 
2 
to 135 minutes in responders (Table 3.26). Contrary to what was expected, 
this would tend to keep plasma levels higher for a longer time period in 
non-responders. 
In humans the plasma concentration of ranitidine at which pentagastrin 
stimulated acid secretion is inhibited by 50% (Ic50 ) is reported to b
e 
92 
TABLE 3.26. Half-life (t;,), area under the curve (AUC) and time 
2 
that concentration remained above 100 ng/ml for non-responders. 
tl AUCO- 12 Time concentration 
Initials 2 greater than 100 ng/ml 
(min) (ng/ml.h) ( h) 
J.S. 189 l 140 4,0 
R.L. 173 l 540 4,75 
D.S. 166 3 584 9,75 
D.M. 154 2 720 7,75 
S.S. 189 3 315 9, 75 
P.P. 173 2 405 8,0 
P.M. 160 3 199 9,25 
median 173 2 720 7,75 
( 135) (2 108) (5,9) 
range 154-189 l 140-3 584 4,0-9.75 
(52-160) ( 1 458-3 074) (5,25-7,75) 
( ) values for responders 
in the region of 100 ng/ml (Peden et al 1979). i~hen the time that plasma 
concentrations remained above 100 ng/ml was examined in responders and in 
non-responders, an apparent bimodal distribution of non-responders was 
observed (Table 3.26). Non-responders fell into two groups at either 
end of the responders' range. The range for responders was 5,25 - 7,75 h 
and J.S. and R.L. had levels above 100 ng/ml for 4,0 and 4,75 h only 
while the 5 other non-responders had levels above 100 ng/ml for 7,75 h 
and longer. 
As a group the AUC values for non-responders did not differ significantly 
from responders, although J.S. and R.L. again fell at the lower end of 
the range (Table 3.26). 
93 
The theoretical plasma concentration-time curves for the multiple dose 
situation are given in Figures 3.17-3.23. 
The proportion of the total ranitidine dose excreted unchanged in the urine 
24 hours post-dosing was highly variable (10-59%) (Table 3.27) and not 
significantly different to responders (10-105%). Creatinine clearance 
(calculated from serum creatinine) is shown in the same table. 
TABLE 3.27. Percentage of total ranitidine dose excreted unchanged 
in the urine in the 24 hours after dosing and creatinine clearance (Ccr) 


























In summary non-responders as a group did not show grossly different 
pharmacokinetic profiles to responders. Two patients (R.L. and J.S.) 
had relatively low plasma levels, FD/V, AUC, combined with high basal 
and maximal acid output. These patients may fall into a subgroup of 
non-responders for whom an increased dose of ranitidine is necessary 
to inhibit acid secretion. One patient (J.S.) did in fact show evidence 
of ulcer healing on endoscopy after one month's treatment at 300 mg twice 
daily; the FD/V was increased to 472 ng/ml, the AUC to 2 789 ng/ml.hr and 
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3.3. PATIENTS SUFFERING FROM CHRONIC RENAL FAILURE. 
3.3.l. Single- and multiple-dose pharmacokinetic studies in patients 
with severe renal failure who were not on haemodialysis. 
The plasma concentration-time data following single dose oral 
administration of 150 mg ranitidine are given in Table 3.28. The multiple-
dose study was carried out after one week of ranitidine being taken twice 
daily. The plasma concentration-time data are given in Table 3.29. I 
have viewed the multiple-dose data with caution for the following reasons: 
B.S. received 150 mg ranitidine twice daily throughout the week while the 
other patients received 75 mg twice daily; B.S. underwent haemodialysis 
3 times during the week of the study although not on the day of study; 
L.A. may have taken 75 mg ranitidine two hours prior to the multiple-dose 
pharmacokinetic study; it is possible that R.W. did not receive the evening 
ranitidine dose on the day prior to the multiple-dose study. 
The maximum (Cmax) and minimum (Cmin) concentrations and the time to reach 
Cmax (tmax) after single- and multiple-dosing are shown in Table 3.30. 
These values are taken from the raw plasma concentration-time data. The 
multiple-dose Cmax and Cmin were normalised for a 150 mg dose. There was 
no apparent difference in the absorption phase of ranitidine in uraemic 
patients, compared with the reference group with duodenal ulceration and 
normal renal function as Cmax and tmax did not differ significantly in 
either the single- or the multiple-dose situation. After single- and 
multiple-dosing in uraemic patients, minimum concentrations (Cmin) were 
highly significantly different to controls. The median Cmin at 12 hours' 
post-dosing after a single-dose in patients with renal failure was 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 3. 31. Akaike's Information Criteria for one- and two-
compartment models in patients with chronic renal failure. 
Single - dose Multiple - dose Initials l Compartment 2 Compartments l Compartment 2 Compartments 
B.S. 118,9 115, 7+ 133,4+ 134,0 
J.Se. 147,3+ 152,0 133,6+ 151 ,4 
L.A. 139,5+ 143 ,8 132,2+ 156,7 
H. D. 120,0+ 123,9 131 ,2+ 146 ,9 
T. C. 159,8+ 169,6 114 ,6+ 120,9 
R. \,J. 121,9+ 123 ,6 93,2+ 124,3 
+ Model chosen for analysis. 
The difference was even greater after multiple dosing with median Cmin 
levels of 270 ng/ml in renal failure and 30 ng/ml in controls (p <0,001). 
The concentration-time data were fitted to both one- and two-compartment 
models and Akaike's Infonnation Criteria (AIC) were calculated in order 
to choose the simplest model (Table 3.31). The one-compartment model 
best described the data in all cases except after single dose administration 
to B.S. where a two-compartment model gave a lower AIC value. 
There were no differences in absorption rate (Ka) or lag time to the 
start of absorption in single- and multiple-dosing between uraemic 
patients and patients with nonnal renal function. There did not appear to 
be any difference in the bioavailability of ranitidine in uraemic patients, 
as FO/V values were not significantly different from controls. 
Elimination of ranitidine was much slower in patients with impaired 
renal function. The median elimination rate constant (Ke1) after single-
106 
TABLE 3.32. Computer-generated pharmacokinetic parameter for single-
dose (A) and multiple-dose (B) studies in patients with renal failure. 
A. 
ka tlag FD/V ke 1 or S Cl 
Initials 
(h-1) (min) (ng/ml) (h-1) ( h - 1 ) 
B. S. 0,74 10,4 85 7, 7 0,07 0 ,78. 
J.Se. 0 ,86 30,0 1 116 ,2 0, 12 
L.A. 3,22 13 ,8 923,4 0, 12 
H. D. 2,28 15,0 335,7 0, 15 
T.C. 0,48 15 ,0 l 132, l . 0, 16 
R.W. l , 79 26,9 857 ,0 0,23 
median 1 ,33 15,0 890 ,6 0, 14** 
(1,31) (19,3) (549,5) (0,31) 
range 0,48-3,22 10 ,4-30 ,0 335 , 7- 1 132 , l 0,07-0,23 
(0,37-3,26) (0 ,0-33 ,8) (229,0-1 138,1)(0,19-0,82) 
B. 
ka tlag FD/Vl kel 
Initials 
( h - 1 ) (min) (ng/ml) ( h -1 ) 
B.S. 1 , 91 12,7 425,7 0, 16 
J.Se. 1 , 41 13,7 l 095,2 0,08 
L.A. 10 ,87 28,8 873,0 0, 14 
H.D. 3,47 15 ,9 601 ,2 0, 11 
T.C. 6, 10 8,8 344,0 0,09 
R.W. 3 ,46 20 ,4 738,6 0, 17 
median 3,47 14,8 669,9 0, 13 
(2,39) (13,2) (850,9) (0,31) 
range 1,41-10,87 8,8-28,8 344,0-1 095,2 0 ,08-0, 17 
(0,70-11,05) (0,0-28,2) (416,2-3 381,l) (0,26-0,80) 
Key: ** p <0,001 
l normalised for dose 
( ) values for controls 
dosing was 0,14 h-l with controls having a median Kel of 0,31 h-l 
(p <0,001). The pattern was similar after multiple-dosing. 
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The median half-life in renal failure was prolonged by approximately two-
fold (312 minutes compared with 135 minutes in controls) (Table 3.33). 
TABLE 3.33. The half-lives (t1) after single- and multiple-dosing 
2 
in patients with renal failure. 
Initials Single-dose t1 
Multiple-dose t1 
(min) 2 (min) 2 
B.S. 594 260 
J.Se. 347 520 
L.A. 347 297 
H.D. 277 378 
T. C. 260 462 
R.W. 181 245 
median 312 338 
( 135) ( 135) 
range 181-594 245-520 
(51-219) (52-160) 
( ) Values for patients with nonnal renal function. 
The theoretical plasma concentration-time curves for patients with 
renal failure are given in Figures 3.24-3.29. Each figure represents 
the single- and multiple-dose curves for a patient. 
The AUC obtained for patients with renal failure were highly variable 
ranging from 2 673-10 270 ng/ml.h after single-dosing, with a similar 
wide range after multiple-dosing. Within this group of patients with 
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of renal impairment as judged by creatinine clearance (r2 = 0,157 after 
single-dosing and r2 = 0,066 after multiple-dosing). 
TABLE 3.34. 
failure. 
AUC (single- and multiple-dose) for patients with renal 
Single-dose Multiple-dose 
Initials AUC AUC l 
(ng/ml.h) (ng/ml.h) 
B.S. 4 147 3 137 
J.Se. 10 270 13 664 
L.A. 7 904 8 958 
H.D. 2 673 6 776 
T. C. 8 313 5 872 
R. \~. 4 286 3 914 
median 6 095** 6 324** 
(l 844) (2 108) 
range 2 673-10 270 3 137-13 664 
(l 304-2 688) (l 458-3 074) 
** p <0,001 
l normalised for dose 
( ) control values 
In Figure 3.30 AUC is plotted against creatinine clearance for both 
patients with renal failure and those with normal renal function. There 
is a possibility that a hyperbolic relationship exists although the exact 
relationship could not be determined as no patients were studied in the 
moderate renal failure range (creatinine clearance 20-60 ml/min). 
However, AUC for the patients with renal failure was significantly 
different to that of patients with normal renal function after both 



















































































































































inversely proportiona1 to clearance, it is assumed that this increase 
is due to decreased renal clearance of ranitidine. 
The amount of ranitidine excreted unchanged in the 24-hour urine 
collection expressed as a percentage of dose for each patient after 
single- and multiple-dosing is shown in Table 3.35, together with the 
uncorrected creatinine clearance calculated from urine creatinine con-
centrations and creatinine clearance estimated from serum creatinine with 
a correction for age, sex and weight (Method 2, Lot and Hayton 1978). 
The latter creatinine clearance was used for calculations and figures. 
In the group of patients with renal failure, the amount of unchanged 
ranitidine in urine was significantly less than that found in the urine 
of patients with normal renal function (p <0,001) with median values of 
5 and 26% respectively. The pattern was similar after single- and multiple-
dosing. 
TABLE 3.35. Amount of ranitidine (% of dose) excreted in the urine in 
the 24 hours following dose; creatinine clearance calculated from urine 












































Ranitidine Ccr(U) Ccr(S) 






























In Figure 3.31 the amount of ranitidine excreted in the 24 hour urine 
collection, expressed as a% of dose is plotted against creatinine 
clearance for both groups of patients after single-dosing. It can be 
seen that within each group there is a wide variation which is not 
apparently related to creatinine clearance. However, when both groups 
are combined there appears to be a linear relationship (r2 = 0,679, 
p <0,001) between amount of ranitidine in the urine and creatinine 
clearance. 
Since neither AUC nor t 1 appears to be directly related to creatinine 
2 
clearance in the patients studied, it is not possible to suggest making 
dosage adjustments oased on creatinine clearance measurements as an index 
of renal function. In the present study the nonnal 150 mg dose was 
arbitrarily halved while maintaining a 12 hour dosage interval for the 
multiple-dose study in 5 of the 6 patients with renal failure. Plasma 
ranitidine levels remained above 100 ng/ml (the IC50 for acid inhibition 
in duodenal ulcer patients) for 8 hours in the 5 patients, with most 
exceeding this level for 12 hours. No untoward central nervous system 
changes were noted by the patient or the doctors. Blood biochemistry and 
haematology were monitored regularly in 4 of the 6 patients who remained 
in hospital for the week of the study. In 3 patients a rise in SGOT 
levels was noted and there was a rise in alkaline phosphatase levels in 
3 patients although no other biochemical tests showed changed levels 
(Appendix II,Table A4). 
Based on the half-life, a two-fold reduction in the 150 mg dose of 
ranitidine would give plasma levels comparable to those in patients with 
normal renal function. Prolonging the dosage interval from 12 to 24 hours 
might result in very low trough levels in patients such as RJJ. and S.S. 
who have relatively small AUC's and trough levels of ranitidine despite 
very poor renal function. 
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3. 3. 2. Dialysance of ranitidine. 
The 3 patients in this study received 150 mg ranitidine, orally, on 
one occasion only. Dialysis was commenced approximately 3 hours after 
administration of the ranitidine tablet. Blood samples were drawn 
approximately 3 hours after the commencement of haemodialysis and in 
two cases this was done at two flow rates (Table 3.36). Ranitidine is 
partially cleared by dialysis with a dialysance of 40 ml/min at a flow 
rate of 175 ml/min and 50 ml/min at a flow rate of 275 ml/min. 
TABLE 3. 36. Concentration into (Bi) and out of (Bo) dialyser, 
flow rate (OB), dialysance (QD) and times after dosage and from start 
of dialysis for 3 patients with chronic renal failure on chronic 
h aemodi al ys is. 
Flow Di alysance Time after Time from Initials Bi Bo rate start of 
QB QD 
dose dialysis 
(ng/ml) (ng/ml) (ml/min) (ml/min) ( h) ( h) 
F.P. 566 463 275 50 6,0 2,83 
448 347 175 39 7,0 3,92 
O.P. 567 466 275 49 5,9 2,67 
484 371 175 41 7, 1 3,83 






It is of importance that the pharmacokinetic behaviour of a drug is 
studied in the patient population that will ulti~ately receive the 
medication, as the absorption, distribution, metabolism or elimination 
of a drug may be altered by the disease state, thereby reducing therapeutic 
effects or increasing the likelihood of toxic effects. In the case of 
ranitidine, it is the ulcer patient or the patient at risk of developing 
ulcers who will receive the drug. It is likely that the elderly patient 
or the patient with renal dysfunction will be most at risk for development 
of adverse effects. 
The present study encompasses a group of patients with duodenal ulceration 
who responded to ranitidine therapy, a subgroup who did not respond, and a 
small number of patients with advanced renal disease who did not have peptic 
ulceration. The results of these three groups will be discussed in that 
order. 
In patients with duodenal ulceration ranitidine was rapidly absorbed, 
reaching peak levels within two hours in most cases. There was a trend 
for the peak to be reached earlier after multiple dosing. There was a lag 
time for absorption varying from nil to approximately half an hour and this 
tended to be a little shorter after multiple dosing. There was a wide 
range in the bioavailability of oral ranitidine (28-76% \vith a mean of 
51%) when this was studied in 4 responders and 1 non-responder. This 
variation has similarly been described for cimetidine in peptic ulcer 
patients and was ascribed to the disease state (Somogyi et al 1980a). The 
findings for ranitidine are in agreement with the 49% (Woodings et al 1980) 
and 52% (Garg et al 1981) bioavailability reported for healthy volunteers, 
although in another study 81% bioavailability has been reported in healthy 
subjects (McNeil et al 1980). In the present study with oral ranitidine 
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relative bioavailability after single- and multiple-dose studies can be 
assessed by comparing the respective FD/V values. The dose remained 
constant and it was assumed that the volume of distribution of the drug 
remains constant in any individual. Thus, any change in FD/'J is attributed 
to the fraction of the dose available systemically. There was a marginal 
increase in the median FD/V with multiple dosing compared ~vith the same 
parameter after single dosing. This increase in rate and extent of 
absorption may in part be due to the more alkaline conditions present in 
the stomach and duodenum in patients receiving ranitidine. This might 
facilitate absorption of ranitidine which is a weak base. Another possible 
explanation is a contribution from the previous dose through enterohepatic 
recycling. In this study no evidence for recycling of ranitidine was found 
12 hours after dosage. However, in another study, bioavailability and 
hepatic and renal clearance values for ranitidine in normal volunteers 
suggest a significant 1 first-pass 1 metabolism following oral administration 
(Garg et al 1981). 
The elimination half-life (t1 ) of 135 minutes in the patients in this 
2 
study after oral dosage corresponds with that reported for healthy volunteers 
(Garg et al 1981, McNeil et al 1980, lfoodings et al 1980). The t 1 after 
2 
intravenous (IV) administration was somewhat shorter, with a median of 61 
minutes. A possible explanation is that the lack of sensitivity of the 
assay method did not allow the very low levels after 6 hours to be accurately 
measured after IV admi ni strati on. In certain patients there appeared to be 
a very slow release from a deep compartment contributing to a longer t 1 after 
2 
the higher oral dose. 
It is interesting to note that although ranitidine has a t 1 only slightly 
2 
longer than the 2 hours of cimetidine (Burland et al 1975, Griffiths et al 
1977, Somogyi et al 1980a, ~falkenstein et al 1978), it has a longer duration 
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of action with adequate control of 24-hour gastric acidity with a twice 
daily dosage schedule (Walt et al 1980, Walt et al 1981). This is borne 
out by clinical evidence of ulcer healing on a twice daily dose schedule 
(Barbier et al 1979, Langman et al 1980). In this respect ranitidine is 
similar to another new H2-antagonist tiotidine (Kaojarern et al 1981). 
Not only is the half-life of ranitidine similar to that of ci~etidine but 
the volume of distribution of the central compartment and volume of 
distribution steady state for ranitidine in this study were very similar to 
values Somogyi et al found in a study of cimetidine pharmacokinetics in 
peptic ulcer patients (Somogyi et al 1980a). McNeil et al found a larger 
total volume of distribution of ranitidine in healthy volunteers than was 
found in this study (McNeil et al 1980). From the present study it appears 
that ranitidine distributes into two compartments with similar volumes of 
distribution to those of the two compartments of cimetidine. In one study 
of cimetidine a 3-compartment model gave the best fit for certain patients 
(Somogyi et al 1980a) and this may be the case with ranitidine although a 
3-compartment model fit was not attempted. 
The mean total body clearance of ranitidine was 680 ml/min in the 5 patients 
studied and this was in agreement with 709 ml/min found in healthy volunteers 
(Garg et al 1980, McNeil et al 1980). The clearance of cimetidine in peptic 
ulcer patients has been reported as 495 ml/min and this was age dependent 
(Somogyi et al 1980a). 
A clear-cut relationship between age and ranitidine disposition such as 
that demonstrated for cimetidine (Somogyi et al 1980a) was not observed 
probably because of the small numbers and narrow age range of patients in 
this study. A surprising age-related increase in Vd t' Vd and Vd ex ss area 
was shown but this was greatly influenced by one patient who happened to 
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be a non-responder and who therefore was possibly not truly representative 
of duodenal ulcer patients. 
No correlation between creatinine clearance and half-life of elimination 
of ranitidine was found but total plasma clearance was related to 
creatinine clearance in the duodenal ulcer patients. The renal clearance 
of cimetidine is less strongly related to creatinine clearance than is 
expected (Somogyi et al 1980a) and ranitidine may be similar. In this 
study renal clearance was not calculated as 24-hour urine collections were 
made in only two cases after intravenous administration. 
All the patients in this study had ranitidine administered together with 
food and the bimodal plasma concentration-time pattern seen with ranitidine 
(Woodings et al 1980) and cimetidine (Bodemar et al 1979, Somogyi et al 
1980a, Walkenstein et al 1978) when administered on a fasting stomach was 
not observed. 
Ranitidine and cimetidine effect similar healing rates and there are non-
responders to ranitidine just as there are patients with cimetidine-
resistant ulcers (Berstad et al 1980, Langman et al 1980). The multiple-
dose phannacokinetic pattern was studied in non-responders in order to 
see if this pattern differed from responders. The degree of inhibition 
of gastric acid in response to ranitidine was not studied in either group. 
In two drug trials of a total of 130 patients only 7 patients who did not 
respond to treatment were considered sufficiently compliant and accordingly 
qualified for inclusion as non-responders (Section 2.2.). Fasting serum 
gastrin levels in all 7 of these patients were within normal limits, ruling 
out the Zollinger-Ellison syndrome as the cause of the lack of response. 
Three of the 6 non-responders in whom gastric acid secretion studies were 
carried out had high basal and maximal acid output compared with the 10 
responders. In addition, two of these had relatively low plasma levels, 
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AUC and FD/V values. This seems to indicate that the standard ranitidine 
dosage of 150 mg twice daily may not be adequate for the control of acid 
in some patients. The lack of response in the other patients cannot be 
as si~ply explained. Non-responders as a group did not differ significantly 
from responders with respect to any of the pharmacokinetic parameters 
besides the half-life which was unexpectedly longer in non-responders. 
Non-responders tended to be older and to smoke ~ore than responders. The 
five patients with plasma levels comparable to responders were of Asiatic 
origin. 
There are a few reports in which investigators attempted to find the reason 
for lack of response to H2-antagonists. There is a single case report where 
acid secretion was unaffected by cimetidine treatment despite adequate 
plasma levels (Kisloff 1980). In another cimetidine study it was observed 
that patients with lower pretreatment rates of gastric acid secretion had 
a higher incidence of ulcer healing and patients with ulcers which healed, 
had a lower mean peak acid output than those whose ulcers had not healed. 
It was suggested that the standard cimetidine dose was inadequate in 
patients with higher secretory rates (Binder et al 1978). In a study of 
duodenal ulcer patients, Rune et al found that a group of patients with a 
low sensitivity to cimetidine and a high maximum acid output improved more 
slowly than other patients (Rune et al 1979). It appears that some patients 
require higher doses and possibly longer treatment periods than others. 
Wormsley et al have identified two subgroups of non-healing patients - one 
group in which acid secretion is not adequately suppressed by standard 
doses of ranitidine, and another group in which residual duodenal ulceration 
was present despite complete suppression of gastric secretion. They found 
the former group to have increased ulcer healing when the dose was increased 
to 300 mg twice daily while the latter were healed by the addition of a drug 
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such as carbenoxo l on to the regime (:Jorms l ey et al 1981). It is therefore 
important to carry out gastric secretory studies of H2-antagonist treatment 
failures in order to treat them correctly. Five of the 7 non-responders 
in the present study were subsequently treated surgically and the remaining 
two are at present being considered for surgery. 
The incidence of peptic ulceration occurring in conjunction with renal 
failure may range from Oto 20% and there is a marked increase (of up to 
50%) when patients undergo chronic haemodialysis (\>Jormsley· 1980). It 
can therefore be anticipated that ranitidine will be administered to 
patients in renal failure. Ranitidine, like cir.ietidine, is excreted 
primarily unchanged by the kidney (Bell et al 1980) and it is therefore 
expected to accumulate when renal function is impaired. 
In the present study the phannacokinetics of ranitidine in advanced renal 
failure (creatinine clearance below 25 ml/min) were compared with those 
in duodenal ulcer patients with normal renal function (creatinine clearance 
above 60 ml/min) in order to minimize toxicity which may occur due to 
accumulation of the drug. At present there is no published information 
concerning the overall elimination rate constant of ranitidine, its t 1 
2 
and the relationship to glomerular filtration rate. 
The absorption of ranitidine in uraemic patients does not differ from 
absorption in the patients with normal renal function in this study. 
Bioavailability, as assessed by FD/V, which is independent of elimination, 
did not differ significantly beb1een the two groups. 
However, there were highly significant differences in the 12-hour minimum 
concentrations, elimination rate constants (and consequently t 1 ) and in 
2 
the areas under the curve (AUC) with very little overlap in any of these 
parameters between the two groups. 
No linear relationships between the degree of renal failure, using 
creatinine clearance as a measure, and half-life could be found. 
Similarly AUC could not be related to creatinine clearance within the 
renal failure group. The probable reason for this lack of correlation 
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is that endogenous creatinine clearance is of questionable value in 
patients with severe kidney disease (Dettli 1976). The possible relation-
ships between creatinine clearance and parameters such as t 1 and AUC could 
2 
not be detennined overall as there was no overlap between the two groups 
with respect to creatinine clearance. It is possible that the relationship 
is hyperbolic.with AUC and t 1 increasing dramatically" only when creatinine 
2 
clearance is below 20 ml/min. 
Since the relationship between accumulation of ranitidine and renal 
function could not be determined, it is not possible to drav, up a nomogram 
for dosage adjustment based on creatinine clearance. 
The median t 1 in the patients with advanced renal failure in my study is 
2 
twice that of the group with normal renal function and AUC was three times 
larger in patients with renal failure. I would suggest a decrease in 
dosage to 75 mg ranitidine administered tv,ice daily in patients vlith 
advanced renal failure (creatinine clearance below 25 ml/min) without 
altering the already long 12-hour dosage interval to lessen fluctuations 
in ranitidine concentrations in the body. 
Ranitidine was well tolerated in all the patients studied, including the 
small sample of patients with severe renal failure. I assumed that 
ranitidine would behave in a similar manner to cimetidine in renal failure 
and therefore halved the standard 150 mg ranitidine dose for chronic 
treatment of patients with renal failure. Despite an approximate 5-fold 
higher trough level (12 hours) found in these patients on reduced dosage 
no side effects were noted. 
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No gastric secretory studies were perfonned on patients with renal 
failure and it is impossible to assess whether plasma concentrations 
obtained were associated with inhibition of gastric acid secretion. 
Assuming comparab 1 e effects on gastric acidity 1vi th those in patients 
with normal renal function, the plasma ranitidine concentrations obtained 
with 75 mg ranitidine are more than adequate. 
Within the group of patients with renal failure there was a wide inter-
individual variation in drug concentrations, t 1 and AUC which bore no 
2 
direct relationship to the degree of renal failure. Two patients with 
advanced renal failure excreted less than 2% of the dose as unchanged 
ranitidine in urine but had the smallest areas under the curve, and another 
patient 1tJith creatinine clearance of 18 ml/min who excreted 16% of dose as 
unmetabolised ranitidine had a relatively large AUC. These differences may 
reflect variation in the apparent volume of distribution of ranitidine or 
perhaps an alternative ranitidine excretory pathway may be utilised in 
younger patients whose other organs such as the liver may be better able 
to cope with drug detoxification. Schentag et al have reported that 
cimetidine trough concentrations were consistently raised only in those 
patients with serious impairment of both renal and liver function (Schentag 
et al 1977). Cimetidine and ranitidine undergo oxidation (Bell et al 1980, 
Burland et al 1975b) and in renal failure oxidation reactions are for the 
most part normal (Reidenberg and Drayer 1980). It would therefore not be 
surprising if in certain patients metabolism by the liver may compensate 
for the renal impairment to some extent. 
On the basis of the present study, it is not possible to make precise 
dosage recommendations for ranitidine administration in renal failure. 
Until further studies are carried out which establish the overall body 
clearance of ranitidine and ranitidine renal clearance over the whole 
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range of renal decompensation, halving of the standard 150 mg ranitidine 
dose would seem advisable, bearing in mind the individual variation. 
Ideally there should be individualization of dose in these patients 
based on monitoring of drug plasma levels. 
In this study ranitidine was found to undergo limited dialysis (50 ml/min). 
An additional dose at the end of the period of haemodialysis would seem 
unnecessary although a standard 150 mg dose on the morning of a day on 
which haemodialysis is carried out, may be useful. 
APPENDIX I 
CASE HISTORIES 
A. Patients with chronic duodenal ulceration 
- responders 
- non-responders 
B. Patients with chronic renal failure 
Abbreviations: GSH - Groote Schuur Hospital 
KE King Edward VIII Hospital, Durban 
NSH New Somerset Hospital, Green Point 
BAO Basal acid output 
MAO - Maximal acid output 







A. PATIENTS WITH CHRONIC DUODENAL ULCERATION 
No. 1 












1975: Duodenal ulcer diagnosed on barium meal, treated with antacids. 
1977: Recurrence of epigastric pain with vomiting and loss of weight. 
Endoscopy showed a defonned duodenum with a healed duodenal 
ulcer. 
1978: June. Epigastric pain and vomiting. Treatment with antacids. 
August. Repeat endoscopy showed a deformed pylorus and in 
the duodenum a small area posteriorly with a healed scar and 
surrounding duodenitis. Treated with antacids. 
FAMILY HISTORY: One brother with peptic ulceration. No other significant 
family hi story. 
PRESENT ILLNESS (November 1979): 
Presented to the Gastrointestinal Clinic with recurrence of 
epigastric pain which had been severe for the previous week. 
He also had sinusitis which was being treated with tetra-
cyclines. 
Endoscopy: defonned pylorus and duodenum with an 0,8 cm 
superior superficial duodenal ulcer just behind the pylorus. 
Pentagastrin stimulated gastric secretory study: BAO 
2,6 meq/h, MAO 16,2.meq/h. 
RESPONSE TO RANITIDINE (December 1979): 
The patient responded symptomatically within one day of the 
initiation of treatment. After 28 days• treatment follow-up 
endoscopy showed the duodenum to be scarred and hyperaemic. 
On the anterior aspect of the greater curve, duodenitis and 
a long linear scar were noted. The patient was placed on 
the maintenance study of ranitidine. 
No adverse effects of ranitidine were noted. 
CONCOMITANT MEDICATION: 
Tetracyclines: 250 mg four times daily were prescribed for 
7 days on two occasions coinciding with the single- and 
multiple-dose phannacokinetic studies. 
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No. 2 







r.1a 1 e 
47,5 kg 
unemployed 
chronic duodenal ulceration 
PAST ILLNESSES: 
1963: From this time onwards chronic dyspepsia. 
1979: Patient had complained of nausea and vomiting for several 
years. In addition he had had a burning sensation in the 
upper abdomen, unrelated to meals, and a poor appetite. He 
was treated with antacids and in 1978 with cimetidine. 
A barium meal examination showed a deformation of the first 
part of the duodenum and an active ulcer. Treatment was 
given with metoclopramide and 11 Mucaine 11 (aluminium hydroxide, 
oxethazaine and magnesium hydroxide). 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (November 1979): 
Despite the above medication there was no abatement of 
symptoms over the previous two months. 
Endoscopy: Stomach showed two small areas of gastritis on 
the greater curve (possibly related to medication) and a 
defonnity of the pyloric antrum. The pylorus was patent. 
A small shallow duodenal ulcer was noted superiorly. 
Pentagastrin stimulated gastric secretory study: BAO 
2,4 meq/h, MAO 27,8 meq/h. 
RESPONSE TO RANITIDINE (December 1979): 
The symptoms abated but did not disappear over the first 
two weeks. Endoscopy at four weeks revealed a small linear 
scar on the anterior duodenal wall. A duodenal diverticulum 
was noted. 
No adverse effects were noted. 
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No. 3 










chronic duodenal ulceration 
PAST ILLNESSES: 
1977: Epigastric pain not related to meals. This had recurred 
off and on over a number of years but had been more 
noticeable in the previous two years. 
Barium meal examination showed a central crater in the 
duodenum. 
Treatment was with antacids with a good response. 
1978: Symptoms returned and were treated with antacids and 
propantheline. 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (March 1980): 
The symptoms had been present for a year but were more 
severe in the previous week. The pain was worse when the 
patient was hungry and at night. 
Endoscopy: The duodenum was deformed withal ,0 x 0,6 cm 
ulcer on the anterior aspect of the greater curve of cap 
which was oedematous with erosive duodenitis surrounding it. 
Pentagastrin stimulated gastric secretory study: BAO 
2,4 meq/h, MAO 26,4 meq/h. 
RESPONSE TO RANITIDINE (April 1980): 
Endoscopy 28 days after initiation of treatment showed 
evidence of ulcer healing but erosions were noted at the 
previous ulcer site. There was duodenitis of the anterior 
wall and two new erosions of the roof of the duodenum. 
The patient complained of tiredness, possibly attributable 
to medication, but there were no other adverse effects. 
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No. 4 
INITIALS AND FOLDER NUMBER: M.S. 55220636 (GSH) 
AGE: 26 years 
SEX: male 
WEIGHT: 50 kg 
OCCUPATION: unemployed 
DIAGNOSIS: chronic duodenal ulceration 
PAST ILLNESSES: 
Epigastric pain and nausea intennittently for several years. 
1980: February. Epigastric pain; barium meal showed a marked 
pyloric spasm and defonnity of the duodenal cap. 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (March 1980): 
Epigastric pain, nausea and haematemesis two nights prior to 
present visit. Right-sided chest pain with coughing and 
breathing had developed. The latter was attributed to 
bronchitis, and tetracyclines were prescribed. 
Endoscopy: Mild gastritis with fundal erosions. The pylorus 
was defonned and oedematous. There was an ulcer crater just 
inside the pylorus, 0,5 cm in diameter, post-inferiorly. 
Pentagastrin stimulated gastric secretory study: BAO 
3,2 meq/h, MAO 25,5 meq/h. 
RESPONSE TO RANITIDINE (April 1980): 
Endoscopy: normal stomach and pylorus with a scar in the 
duodenal cap. 
No adverse effects to ranitidine were noted. 
CONCOMITANT MEDICATION: 
Tetracyclines 250 mg 4 times daily for 7 days after 
initiation of ranitidine therapy. 
No. 5 
INITIALS AND FOLDER NUMBER: S.M. 54606942 (GSH) 
AGE: 31 years 
SEX: male 
WEIGHT: 57 kg 
OCCUPATION: gardener 
DIAGNOSIS: chronic duodenal ulceration 
PAST ILLNESSES: 
1978: The patient had a duodenal ulcer which was treated with 
cimetidine. 
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1979: On endoscopy the patient was found to have a polyp in the 
stomach as well as gastritis. 
In the duodenum there was a superficial ulcer 0,4 cm in size 
in the base of the cap. This was treated with antacids. 
FAMILY HISTORY: There is no history of ulcer disease in the family. 
PRESENT ILLNESS (March 1980): 
The patient presented with continuous epigastric pain which 
was not relieved by antacids. 
Endoscopy: There was a swollen pre-pyloric fold, inferiorly. 
In the duodenum there was an 0,4 cm ulcer at the beginning 
of the second part. 
RESPONSE TO RANITIDINE (April 1980): 
The patient responded symptomatically within 7 days of 
initiation of therapy. 
Endoscopy: The ulcer was healed but erosions were present. 
Six months later while the patient was on maintenance 
ranitidine therapy, he returned for a bioavailability study 
when ranitidine was administered intravenously in a dose of 
20 mg. An ECG was done after administration of the drug: 
rate 65, sinus rhythm, occasional ventricular premature 
systole beats, PR= 0,16 secs, normal axis, voltage changes 
of left ventricular hypertrophy. 
No untoward effects were noted while he was treated with 
ranitidine. 
No. 6 
INITIALS AND FOLDER NUMBER: D.F. 57465502 (GSH) 
AGE: 23 years 
SEX: male 
WEIGHT: 48 kg 
OCCUPATION: machinest 
DIAGNOSIS: chronic duodenal ulceration 
PAST ILLNESSES: 
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A two year history of epigastric pain, nausea and occasional 
vomiting after meals. These symptoms were usually relieved 
by antacids. 
1980: April. Symptoms became more severe. 
Barium meal examination showed a grossly deformed duodenal 
cap and an ulcer crater with radiating folds. 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (May 1980): 
Endoscopy: The pylorus was narrowed and the duodenum was 
deformed and hyperaemic. An oval ulcer, 0,4 by 0,8 cm, was 
seen on an oedematous mound in the anterior aspect of the cap. 
RESPONSE TO RANITIDINE (June 1980): 
The patient became asymptomatic within one week. 
Endoscopy done 4 weeks after initiation of therapy showed 
coffee grounds in the fundus and antrum. In the duodenum 
an oedematous mound was noted in the roof of the cap with 
an erosion on top of it. 
No. 7 
INITIALS AND FOLDER NUMBER: P.d.J. 55627772 (GSH) 
AGE: 24 years 
SEX: male 
WEIGHT: 50 kg 
OCCUPATION: clerk 
DIAGNOSIS: bleeding duodenal ulcer 
PAST ILLNESSES: 
1973: He had had a barium meal and barium enema with negative 
results. 
1974: Operation for haemorrhoids. 
1979: Repeat operation for haemorrhoids. 
The patient had suffered from frequent headaches over a 
number of years for which he had taken salicylates. 
FAMILY HISTORY: No family history of peptic ulcer disease. 
PRESENT ILLNESS (July 1980): 
The patient presented with epigastric pain unrelated to 
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meals but which was worse in the morning. There was no 
improvement with antacids. Patient had noticed a melaena 
stool two weeks prior to admission and again immediately prior 
to admission. No haematemesis was noted. 
A barium meal examination showed a 0,75 cm ulcer crater in 
the duodenal bulb. 
Endoscopy: Blood-stained fluid was noted in the stomach and 
in the duodenum two ulcers - a 1 ,0 cm ulcer on the posterior 
curve and a 0,6 cm ulcer on the floor of the anterior wall. 
Alkaline phosphatase levels were slightly raised. 
RESPONSE TO RANITIDINE (August 1980): 
Endoscopy: After 28 days• ranitidine therapy there was 
complete healing of the posterior wall ulcer with a pit 
and two peripheral ulcers remaining. The anterior ulcer was 
now a large shallow erosion. The patient was asymptomatic. 
The patient was at that stage given 20 mg ranitidine intra-
venously for a pharmacokinetic study without ill effect. 
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No. 8 
INITIALS AND FOLDER NUMBER: W.M. 54127576 (GSH) 
AGE: 34 years 
SEX: male 
WEIGHT: 64,5 kg 
OCCUPATION: unemployed seaman 
DIAGNOSIS: chronic duodenal ulceration 
PAST ILLNESSES: 
1965: Pulmonary tuberculosis. 
1978: Patient complained on a number of visits to the hospital of 
low backache which may have been related to a fall a few 
months earlier. X-ray did not reveal anything wrong. 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (July 1980): 
1980: August. The patient complained of severe epigastric pain 
over the previous ten days, particularly related to meals. 
This was apparently brought on by a heavy bout of alcohol. 
Barium meal examination showed prominent duodenal ulcer. 
Endoscopy: Some defonnity of the antrum was noted. In 
the duodenum there was a 0,8 cm ulcer on big fold in the 
roof of cap, which was oedematous and hyperaemic. 
Blood chemistry: Raised gamma glutamyl transpeptidase was 
probably related to alcohol. 
RESPONSE TO RANITIDINE (August 1980): 
After treatment the patient felt much better. 
Endoscopy: The duodenum showed a swollen fold with 
duodenitis and an ulcer scar on posterior wall side of roof. 
This patient received an intravenous dose of 20 mg ranitidine 
with no ill effect. 
An ECG done after administration of the drug was nonnal. 
The gamma glutamyl transpeptidase levels were nonnal at 
the end of 4 weeks' treatment with ranitidine. 
No. 9 
INITIALS AND FOLDER NUMBER: A.O. 58016478 ( GSH) 
AGE: 42 years 
SEX: male 
WEIGHT: 73 kg 
OCCUPATION: unemployed 
DIAGNOSIS: active duodenal ulcer disease 
PAST ILLNESSES: 
The patient had a four month history of dyspepsia. 
1980: · July. On barium meal examination the duodenum was not 
adequately visualized and a duodenal ulcer could not be 
excluded. 
FAMILY HISTORY: No gastrointestinal disease in the family. 
PRESENT ILLNESS (August 1980): 
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The patient had symptoms of post-prandial epigastric pain 
with pain at night. Antacids gave moderate relief of pain. 
There was loss of appetite. 
Endoscopy: A swollen circumferential fold with a 0,6 x 
0,4 cm ulcer at its base was seen in the duodenum. 
RESPONSE TO RANITIDINE (September 1980); 
The patient responded symptomatically. 
Endoscopy: The duodenum was defonned. The mucosa tended 
to pit of anterior wall on the greater curve. There 
were multiple small erosions at the site of the ulcer. 
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No. 10 
INITIALS AND FOLDER NUMBER: D.S. 610087 (GSH) 
AGE: 36 years 
SEX: male 
WEIGHT: 94 kg 
OCCUPATION: works in the medical school animal house 
DIAGNOSIS: chronic duodenal ulcer disease 
PAST ILLNESSES: 
There is a longstanding history of duodenal ulceration. 
1971: There was a duodenal ulcer presenting as a melaena which was 
treated with antacids. 
1976: Barium meal examination showed a duodenal ulcer crater in 
the duodenal cap with accompanying defonnity. 
1977: The patient took part in a cimetidine trial. A 0,4 x 0,4 cm 
duodenal ulcer healed when treated with cimetidine. 
1979: The patient presented with epigastric pain and a burning 
sensation. On endoscopy a 0,4 cm duodenal ulcer with duodenitis 
was seen. He was treated with cimetidine and antacids. 
The patient had a moderate to heavy intake of alcohol. 
FAMILY HISTORY: Mother was diabetic but no history of gastrointestinal 
disease in the family. 
PRESENT ILLNESS (September 1980): 
The patient had a recurrence of symptoms with hunger pains 
and flatulence. 
Endoscopy: A 0,3 cm duodenal ulcer in the roof of cap with 
surrounding duodenitis was seen. 
RESPONSE TO RANITIDINE (October 1980): 
The patient became asymptomatic soon after starting 
ranitidine therapy. 
Endoscopy: After 4 weeks' ranitidine treatment, the duodenum 
was defonned with radiating folds from the area of the previous 
ulcer. 
The patient received an intravenous dose of 20 mg ranitidine 
on one occasion. The drug was well tolerated with no change 
in blood pressure or pulse rate. An ECG done at this stage 
showed voltage changes indicative of left ventricular 
hypertrophy. 
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CHRONIC DUODENAL ULCER PATIENTS (NON-RESPONDERS) 
No. 11 
INITIALS AND FOLDER NUMBER: J .s. 56670052 (GSH) 
AGE: 52 years 
SEX: male 
WEIGHT: 66 kg 
OCCUPATION: supervisor at a meat factory 
DIAGNOSIS: duodenal ulceration, polycythaemi a vera 
PAST ILLNESSES: 
1974: Since 1974 the patient has had dyspepsia with classical 
periodicity. Discomfort occurred up to half an hour after 
meals and was relieved by vomiting and alkalis. 
1979: There was a two year symptom-free period until the current 
episode of severe epigastric pain which was unrelated to 
meals and was worse when he lay on his right side. He had 
three episodes of melaena but no haematemesis. The patient 
was a heavy drinker (up to a bottle of wine per day) up 
until a few months prior to admission. 
FAMILY HISTORY: One sister suffers from duodenal ulcer disease. 
PRESENT ILLNESS: (January 1980) 
The patient did not respond to conservative therapy. An 
endoscopy in November 1979 showed a swollen and closed 
pylorus while the duodenum was oedematous and deformed. 
There was a large ulcer 0,8 cm in diameter, inferior to the 
duodenal cap. The patient was entered into the ranitidine 
trial. 
In March 1980 the patient was still symptomatic and on 
endoscopy an ulcer was still present (0,4 cm on floor of cap 
just immediately distal to the pylorus) despite two months of 
ranitidine treatment. A detailed pharmacokinetic study was 
performed and it was found that the plasma levels of ranitidine 
were relatively low. The dose was therefore increased from 
150 to 300 mg twice daily. 
Two weeks later the patient was admitted to hospital because 
of raised liver enzymes thought to be related to an alcoholic 
binge, which soon returned to nonnal. A liver scan revealed 
slight hepatomegaly with no intra-hepatic focal lesions. The 
spleen was slightly enlarged on posterior view. 
Gastric secretion test: BAO 16,5 meq/h, MAO 45,9 meq/h. 
Gastrin: 12,2 pg/ml. 
Chest X-ray: mild hyperinflation. 
There was a raised haemoglobin of 18,8 g/dl but no other 
features of polycythaemia vera. 
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After one month of high dose ranitidine treatment, 
endoscopy showed that the duodenum was defonned and there 
was mild duodenitis, but the ulcer was healed and a linear 
scar remained. The deformity had improved. 
The patient subsequently had a recurrence of the ulcer 
and was treated with sucralphate with some temporary 
improvement. When symptoms again became severe, he was 
treated with cimetidine. This was not effective and the 
patient was later sent for surgery. 
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No. 12 
INITIALS AND FOLDER NUMBER: R.L. 5624059 l (GSH) 
AGE: 50 years 
SEX: male 
WEIGHT: 67 kg 
OCCUPATION: cleaner 





There was a longstanding history of peptic ulcer disease. 
He was treated at Somerset Hospital for duodenal ulceration. 
He was again treated at Somerset for the same complaint. 
The patient complained of weakness and stiffness in the arms 
and legs. This was diagnosed as cervical spondylosis with 
compression. He was operated on for this condition in 
August. A decompressive cervical laminectomy was carried out. 
FAMILY HISTORY: No significant family history. 
PRESENT ILLNESS (April 1980): 
The patient was referred to the Gastrointestinal Clinic 
because of recurrent epigastric pain. 
Endoscopy: The patient was found to have a duodenal ulcer 
in the superior position with anterior erosions and duodenitis. 
Acid test: BAO 12,2 meq/h. MAO 54,9 meq/h. 
RESPONSE TO RANITIDINE: 
1980: May. On endoscopy one prepyloric ulcer erosion was seen 
and also an ulcer 0,5 x 0,3 cm in the roof of the duodenal 
cap. There were surrounding duodenal erosions and erosions 
on the anterior wall. 
1980: June. The endoscopy showed a deformed pylorus and cap with 
a small 0,3 x 0,1 cm ulcer on roof and duodenitis at one 
edge. Fasting serum gastrin levels were normal. 
1980: July. On repeat endoscopy a superior 0,4 cm ulcer with 
deformity and duodenitis were seen. 
At this stage it was decided to increase the ranitidine dose 
from 150 mg twice daily to 300 mg twice daily. The patient 
did not return for his next appointment and was not seen 
until hospitalized for the laminectomy operation. 
1980: September. The patient was then brought back for a pharmaco-
kinetic study following 20 mg ranitidine given intravenously. 
This study was completed without problems except that the 
patient complained of epigastric pain. He had an endoscopy 
at this point and was again found to have a large duodenal 
ulcer. He was treated with cimetidine. 




INITIALS: D.S. (KE) 
AGE: 56 years 
SEX: male 
WEIGHT: 72 kg 
OCCUPATION: worker in sweet factory 
DIAGNOSIS: duodenal ulceration, diabetes mellitus. 











Five year history of recurring dyspepsia. 
ILLNESS: 
October. Patient presented to the clinic with symptoms 
of nausea and vomiting which had worsened over the 
previous 3 months. 
Endoscopy showed a small antral nodule which was biopsied. 
A single deep anterior duodenal ulcer was noted. The 
patient was treated vJith placebo for 28 days. 
Endoscopy after 28 days sho1t1ed gastritis and a single deep 
duodenal ulcer. Patient then started raniti dine therapy. 
November. An endoscopy showed stomach and oesophagus to 
be normal but multiple flat ulcers were noted in the duodenum. 
Another l month course of ranitidine was prescribed. 
January. Patient complained of slight epigastric pain. 
Endoscopy showed area of flat ulceration on a broad ridge. 
April. Ranitidine was discontinued and treatment with 
colloidal bismuth subcitrate was initiated. 
May. The patient was much improved although endoscopy still 
showed ulceration. 
June. Endoscopy showed scanty ulcers. 
March. In the intervening months the patient was treated 
with colloidal bismuth.subcitrate bu: symptoms recurred. 
Surgery is at present being considered. 
CONCURRENT MEDICATION: 
Ch 1 orpropami de. 
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No. 14 
INITIALS: D.M. (KE) 
AGE: 20 years 
SEX: male 
WEIGHT: 54 kg 
OCCUPATION: factory hand 
DIAGNOSIS: chronic duo den a 1 ulceration 
FAMILY HISTORY: 
There are two brothers who have had surgical treatment 








4! year history of dyspepsia. 
ILLNESS: 
October. Patient presented with severe epigastric pain, 
nausea and vomiting. 
Endoscopy revealed gross pylorospasm with a deep, superior 
duodena 1 ulcer. 
Gastric secretion test: BAO 29,4 meq/h, MAO 93,9 meq/h, 
PAO 122,4 meq/h. 
Started treatment with ranitidine. 
November. A deep posterior duodenal ulcer was seen on 
endoscopy. Patient continued on ranitidine. 
January. Patient still complained of epigastric pain 
although not as severe as previously. 
Endoscopy showed a normal stomach and oesophagus. There was 
duodenitis, a deformed duodenal cap and a large duodenal 
ulcer with extensive f1at ulceration. 
February. After a further month's ranitidine treatment, 
endoscopy showed multiple prepyloric and duodenal ulcers. 
There was duodenitis, a defonned duodenal cap and erosions. 
The patient was experiencing severe pain and nausea. 
Ranitidine treatment was discontinued. 
July. Ranitidine treatment was recommenced one week prior 
to the pharmacokinetic study. The patient was subsequently 













DIAGNOSIS: diabetus mellitus, chronic duodenal ulceration 
PAST ILLNESSES: 
Diabetes mellitus. 
1979: February. Gastric 
MAO 55,6 meq/h. 
20 year history of dyspepsia. 
secretion test: BAO 7,4 meq/h, 
FAMILY HISTORY: No significant family history 
PRESENT ILLNESS: 
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1979: October. There were symptoms of epigastric pain, nausea, 
vomiting and acidity over the previous 4 months. On 
endoscopy there was a large deep anterior duodenal ulcer 
enveloping the pylorus. 
Gastric secretion test: BAO 1 ,6 meq/h. MAO 33,7 meq/h, 
PAO 37,8 meq/h. 
Patient was treated with ranitidine. 
1979: November. Patient reported slight epigastric pain with 
nausea and vomiting. 
Endoscopy showed no improvement of the large deep duodenal 
ulcer enveloping the pylorus. 
There was 1% sugar in the urine. 
Patient continued on ranitidine. 
1979: December. Repeat endoscopy showed no change in the large 
deep duodenal ulcer enveloping the pylorus. 
Ranitidine was continued for a further month at the 
standard 150 mg twice daily dosage. 
1980: January. The patient was still experiencing some epigastric 
pain although the endoscopy showed that the duodenal ulcer 
was healing. + Sugar in the urine was noted. 
1980: May. Patient was treated with colloidal bismuth subcitrate 
but endoscopy showed a scarred narrow pylorus with an active 
duodenal ulcer. Patient was referred to the surgeons. 
1980: July. Ranitidine treatment was recommenced for one week 
prior to the pharmacokinetic study. 
1980: September. Prior to surgery a gastric secretion test was 





INITIALS: p. p. (KE) 
AGE: 24 years 
SEX: male 
WEIGHT: 57 kg 
OCCUPATION: cleaner at hospita 1 
DIAGrws IS: chronic duodenal ulceration 
FAMILY HISTORY: no significant family history 
PAST ILLNESSES: 
Recurrent episodes of dyspepsia 
1979: May. Gastric secretion test: 
meq/h, PAO 37,6 meq/h. 
PRESENT ILLNESS: 
from 1974 onwards. 
BAO 4,4 meq/h, ~AO 30,4 
1979: October. Patient complained of 1 acid 1 , full feeling, nausea 
and vomiting which had been recurring over the previous two 
man ths. . 
Endoscopy showed stomach and oesophagus to be normal but a 
single deep inferior duodenal ulcer was present. 
The symptoms worsened over two weeks while the patient was 
on placebo. He was therefore placed on ranitidine therapy. 
1979: November. The patient still had slight pain although he 
was much improved. The endoscopy done 28 days after 
initiation of ranitidine therapy showed a deep inferior 
duodenal ulcer to be present. He continued on ranitidine. 
1980: January. Symptoms were much improved although still present. 
Endoscopy showed a single small duodenal ulcer. 
The patient was subsequently treated with colloidal bismuth 
subcitrate except for a week in July when ranitidine was 
administered prior to the pharmacokinetic study. 












labourer in sweet factory 
chronic duodenal ulceration 
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FAMILY HISTORY: One brother has gastric proble~s. No other significant 
family history. 











October. Epigastric pain, nausea and acidity had been 
experienced. 
Endoscopy showed a pyloric channel ulcer on the lesser curve. 
There were multiple duodenal ulcers, gross distortion with 
flat anterior ulcer plus a deep posterior ulcer. Treatment 
was with placebo for the first 28 days. 
November. Slight epigastric pain was present after one 
month's placebo treatment. 
Endoscopy showed no improvement of the multiple duodenal 
ulcers. Ranitidine treatment was initiated. 
December. Patient became asymptomatic after 2 weeks 1 
rani ti dine treatment. Endoscopy at 4 .,.,eeks showed the 
small deep duodenal ulcer to be active although the flat 
ulceration had healed. 
Ranitidine treatment was continued. 
January. The single small duodenal ulcer on endoscopy was 
noted to be healing. 
Colloidal bismuth subcitrate treatment was commenced. 
February. Patient was asymptomatic although an ulcer was 
still present as well as a small hiatus hernia. 
July. Ranitidine phannacokinetic study was performed. 
August. Patient had a relapsed duodenal ulcer. 
March. Patient was referred for surgery. 
Gastric secretion test: BAO 4,4 meq/h, MAO 25,3 meq/h, 
PAO 28,2 meq/h. 
CASE HISTORIES 
B. PATIENTS lHTH RENAL FAILURE 
No. 1 
INITIALS AND FOLDER NUMBER: B.S. 072043 (NSH) 
AGE: 35 years 
SEX: male 
WEIGHT: 64,5 kg 
OCCUPATION: manager of a garage 
DIAGNOSIS: chronic glomerulonephritis (proliferative) 





1971: Symptoms started when the patient developed swelling of the 
body and pain in the right loin with dysuria and nocturia. 
1975: He developed haematuria and proteinuria. Renal biopsy showed 
features compatible vlith those of acute focal glomerulonephritis. 
Blood pressure was 120/70. The heart was not enlarged clinically 
or radiologically. Intravenous pyelogram (I.V.P.) was normal, 
as was renal size. 
1979: He was admitted with severe headaches and in addition dull 
loin pain. Blood pressure was 190/120. Grade 3 retinopathy. 
2+ proteinuria. Twelve hour creatinine clearance was 15,5 
ml/min. Serum creatinine 625 µmol/1. Blood urea 20 mmol/1. 
Protein excretion 4,9 gm/24 hrs. I.'/.P. at this stage showed 
extremely poor renal function. The fall-off in renal function 
was attributed to hypertension or progression of nephritis. 
His hypertension was fairly easily controlled on atenolol 
100 mg daily, hydrallazine 100 mg twice daily. An additional 
problem was recurrent attacks of headache put down to migraine. 
1980: May. Blood pressure on readmission was 210/120. This was 
brought down to 150/90 with the same antihypertensive treatment. 
1980: July. He was readmitted because of deteriorating renal function. 
Blood urea was 35 ~mol/1. Serum creatinine 1 175 µmol/1. 
Creatinine clearance 5 ml/min. 
X-ray of chest showed slight cardiomegaly. He was admitted 
to the long-term renal failure programme. An arterio-venous 
fistula was inserted. 
1980: September and October. He came back into hospital because of 
fluid overload. 
FAMILY HISTORY: No significant family history. 
150 
HOSPITAL COURSE: 
The patient was excreting approximately l 500 ml urine/day. 
Blood pressure was 140/100. Serum creatinine was l 800 µmol/1 
Serum urea was 145 mmol/1 on the strength of which he was 
entered into the dialysis programme on the day after starting 
the ranitidine treatment. His blood pressure was controlled 
with atenolol, hydrallazine and furosemide. 
The patient felt well throughout the week of ranitidine 
therapy. 
CONCOMITANT THERAPY: 






INITIALS AND FOLDER NUMBER: J.S. 0123810 (NSH) 
AGE: 39 years 
SEX: male 
WEIGHT: 73 kg 
OCCUPATION: school teacher 
DIAGNOSIS: malignant hypertension 
chronic renal failure 
accelerated hypertension 





1974: In July/August he was admitted with epistaxis. Blood pressure 
was 220/150 although this settled rapidly on hospitalization 
to 150/110. There had been blurring of vision for several 
weeks. 
X-ray chest: heart slightly enlarged and left ventricular 
in configuration. Blood urea 56 mg%, creatinine l ,5 mg%. 
Treatment was with alpha-methyldopa and furosemide. 
1978: January. He was readmitted following deterioration with 
severe occipital headaches and recent development of nocturia. 
3+ proteinuria. The patient had mild normochromic normocytic 
anaemia. Haemoglobin 11 ,8 g/dl. Creatinine clearance 6,8 
ml/min. I.V.P. showed both kidneys to be 10 cm in length. 
Diazoxide was necessary to control the blood pressure. 
1980: March. Readmitted due to lack of compliance, elevation of 
blood pressure and development of chest pain, thought to be 
angina pectoris. Blood pressure 150/95. Urine normal. 
No evidence that the patient had had an acute myocardial 
infarction. 
FAMILY HISTORY: Both parents were hypertensive. 
HOSPITAL COURSE: The patient felt well throughout the study. Blood 
pressure was in the order of 160/100. Ranitidine was well 
tolerated despite high plasma ranitidine levels. 
CONCOMITANT THERAPY: 
hydrallazine 75 mg four times daily 
atenolol 100 mg twice daily 
furosemide 120 mg daily 
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No. 3 
INITIALS AND FOLDER NUMBER: L.A. 087207 (NSH) 
AGE: 75 years 
SEX: female 
~EIGHT: 57,5 kg 
OCCUPATION: retired 
DIAGNOSIS: longstanding insulin diabetic 
longstanding insulin-dependent diabetic with hypertension 
transient cerebral ischaemia with left-sided weakness 
chronic renal impairment 
PAST ILLNESSES: 
1963: She had diabetes mellitus (insulin-dependent) and was 
hypertensive for the past 17 years. 
1980: July. The patient was admitted to hospital and on examination 
had mild left-sided hemiparesis. Blood pressure 180/90. 
Pulse 52/min. Presumptive evidence of digoxin toxicity as 
pulse increased on stopping digoxin. Serum creatinine 
200 µmol/1 and urea 12 ~mol/1. 
Chest X-ray showed minimum cardiomegaly. ECG showed some 
left ventricular strain and damage. No protein in the urine. 
Transient cerebral ischaemia. 
FAMILY HISTORY: No significant family history. 
HOSPITAL COURSE: 
No change in the patient's condition during the week of 
treatment. She felt very well while taking ranitidine. 
CONCOMITANT MEDICATION: 
80 lente insulin 35 units daily 
digoxin 0,125 mg daily 
dipyridamole 50 mg daily 
acetyl salicylic acid l daily 
cyclopenthiazide with potassium chloride two tablets daily 
No. 4 
INITIALS AND FOLDER NUMBER: H.D. 260804 
AGE: 34 years 
SEX: male 
WEIGHT: 55 kg 
OCCUPATION: head porter at a hotel 
DIAGNOSIS: acute gl omerul onephri tis 
malignant hypertension 
probable acute tubular necrosis 
microangiopathic haemolytic anaemia 
PAST ILLNESSES: 
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1974: Pulmonary tuberculosis (T.B.). He was carefully followed up 
with annual checkups and was perfectly well unti 1 1980. 
1980: October. He presented with sore throat, shortness of breath, 
ankle and facial oedema, loin pain. This brought him to 
hospital where he was admitted in a serious condition. He 
was in cardiac failure and had pulmonary oedema. The jugular 
venous pressure was raised +6 cm. Blood pressure 280/160. 
There was parasternal heave and a gallop rhythm was hea~d. 
No papilloedema but florid grade 3 hypertensive changes were 
seen in the retina. 3+ proteinuria. 2+ haematuria. 
X-ray of chest showed evidence of old pulmonary T.B. Electro-
cardiograph (ECG) showed evidence of left ventricular hyper-
trophy. 
No acid fast bacilli were found in the sputum. 
Renal biopsy: Four glomeruli showing slight hypercellularity 
and one with fairly advanced sclerosis. These changes could 
not account for the anuria present at the time nor the hyper-
tension. No evidence of fibrinoid necrosis. No obvious 
cause for the anuria could be found. The patient underwent 
peritoneal dialysis. Anuria lasted 8-9 days and then settled 
rapidly. There was evidence of microangiopathic haemolytic 
anaemia. 
Control of blood pressure was achieved with labetalol, 
hydrallazine, guanethadine and furosemide. 
FAMILY HISTORY: No significant family history. 
HOSPITAL COURSE: During the week of ranitidine therapy, the patient 1 s 
condition remained stable. No adverse effects to ranitidine 
were noted. 
CONCOMITANT THERAPY: 
hydrallazine 150 ~g 12 hourly 
furosemide 750 mg daily 
labetalol 200 mg 8 hourly 
No. 5 
INITIALS AND FOLDER NUMBER: T.C. 259879 (NSH) 
AGE: 40 years 
SEX: male 
WEIGHT: 68,5 kg 
OCCUPATION: labourer with the South African Railways 
DIAGNOSIS: previous acute glomerulonephritis 
chronic glomerulonephritis 





Childhood: repeated sore throats and tonsillitis, the last 
attack occurring 10 years ago. 
1956: Epileptic attacks which continued until 5 years ago. 
1970: Fractured left wrist. 
1976: Acute nephritis associated with hypertension. This attack 
lasted 1 month. 
1980: In May he was admitted with severe hypertension. Blood 
pressure 220/140. Blood urea 26 mmol/1. Serum creatinine 
685 µmol/1. Haemoglobin 9,8 g/dl. Proteinuria 3+. 
1980: The patient was admitted again in October. On examination 
he was found to be pale and had peripheral oedema. Pulse 
72/min, regular. Blood pressure 230/145. Clinical evidence 
of left ventricular hypertrophy. A2 was accentuated. 
Proteinuria 4+. Fundi showed grade 3 retinopathy. 
Electrocardiograph showed left ventricular hypertrophy and 
strain. 
Chest X-ray showed no obvious cardiomegaly. Abdomen X-ray 
showed the right renal outline to be 11 ,2 cm. The left kidney 
was not visualised to assess size. 
X-ray hand and midstream urine were normal. Astrup normal. 
FAMILY HISTORY: One aunt has hypertension. No other family history of 
hypertension. 
HOSPITAL COURSE: (while on ranitidine) 
Put out 1 500-2 200 ml of urine daily. Weight remained 
constant. Felt well throughout the admission. Blood pressure 
(standing) was in the order of 190/110, settling during the 
week's hospitalization to 130/90. The recumbent blood pressure 
during the course of the week was fairly constant at 150/100. 
At the time of discharge blood pressure was 220/110. 
No adverse effects to ranitidine were noted. 
CONCOMITANT THERAPY: 
hydrallazine 50 mg 4 times daily 
atenolol 100 mg daily 
furosemide 250 mg daily 
aluminium hydroxide gel 20 ml 4 times daily 
hydrallazine 6,125 mg intramuscularly was administered when the 
diastolic blood pressure went above 120. 
No. 6 
INITIALS AND FOLDER NUMBER: R.W. 267080 (NSH) 
AGE: 21 years 
SEX: male 
WEIGHT: 60 kg 
OCCUPATION: labourer 




Childhood: Renal problems from the age of 11 years. He had 
frequent urinary tract infections. He was investigated at 
Livingstone Hospital for rheumatic fever, outcome of which 
is unknown. 
1981: The patient was weak and unwell for a week prior to admission 
on 2 February. He had nocturia for about three weeks before 
admission. Dysuria was followed by an acute illness which 
had lasted for about 10 days. There was swelling of the legs. 
Examination on admission showed the patient to be confused, 
drowsy, sick and distressed. The face was puffy and the 
body oedematous. Pulse 60/min. Blood pressure 210/140. 
Jugular venous pressure raised+ 3 cm. 
Heart in anterior axillary line suggesting left ventricular 
hypertrophy. Slight systolic murmur. Proteinuria 2+. 
Blood l+. ECG showed sinus rhythm. 
Problems were acute or chronic renal disease with hypertension 
and anaemia. 
The patient underwent peritoneal dialysis. The fluid 
overload was controlled but severe hypertension and uraemia 
persisted. 
Small kidneys bilaterally on X-ray suggestive of chronic 
glomerulonephritis. Excretion concentrate extre~ely poor. 
The fundi showed narrowed arterioles. High K+ levels. 
FAMILY HISTORY: Mother has asthma. 
HOSPITAL COURSE (while on ranitidine): 
The patient did not feel well. This was, however, not thought 
to be due to ranitidine but to the renal disease. Urinary 
output was dropping slightly. Blood pressure was controlled; 
he was in fluid balance with slight ankle oedema. Jugular 
venous pressure was not raised. 
CONCOMITANT THERAPY: 
prazosin 4 mg 8 hourly 
aluminium hydroxide gel 10 ml 3 times daily 
kayexalate 15 g 4 times daily 
DIALYSIS PATIENTS 
No. 1. 
INITIALS AND FOLDER NUMBER: F.P. 129843 (NSH) 
DIAGNOSIS: nephrotic syndrome 









INITIALS AND FOLDER NUMBER: O.P. 217942 (NSH) 





INITIALS AND FOLDER NUMBER: R.D. 211716 (NSH) 
DIAGNOSIS: chronic renal failure 
hypertension 
pneumonia 




TABLE Al. Haematology of patients with chronic 
duodenal ulceration - responders 
TABLE A2. Blood biochemistry of patients with chronic 
duodenal ulceration - responders 
TABLE A3. Haematology of patients with chronic renal 
fai 1 ure 
TABLE A4. Blood biochemistry of patients with chronic 
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